Despite many scientific advances, human exposure to, and intoxication by, toxic metal species continues to occur. Surprisingly, little is understood about the mechanisms by which certain metals and metal-containing species gain entry into target cells. Since there do not appear to be transporters designed specifically for the entry of most toxic metal species into mammalian cells, it has been postulated that some of these metals gain entry into target cells, through the mechanisms of ionic and/or molecular mimicry, at the site of transporters of essential elements and/or molecules. The primary purpose of this review is to discuss the transport of selective toxic metals in target organs and provide evidence supporting a role of ionic and/or molecular mimicry. In the context of this review, molecular mimicry refers to the ability of a metal ion to bond to an endogenous organic molecule to form an organic metal species that acts as a functional or structural mimic of essential molecules at the sites of transporters of those molecules. Ionic mimicry refers to the ability of a cationic form of a toxic metal to mimic an essential element or cationic species of an element at the site of a transporter of that element. Molecular and ionic mimics can also be sub-classified as structural or functional mimics. This review will present the established and putative roles of molecular and ionic mimicry in the transport of mercury, cadmium, lead, arsenic, selenium, and selected oxyanions in target organs and tissues. D
Introduction Metals, including essential and nonessential species, make up a significant fraction of all elements. Nutritive (essential) metals, such as copper (Cu), zinc (Zn), and iron (Fe), are required for normal cellular processes in both prokaryotes and eukaryotes, and thus, there are mechanisms in place to regulate their cellular uptake and accumulation. In contrast, toxic (nonessential) metals, such as mercury (Hg) , cadmium (Cd), and lead (Pb) have no known nutritive Fig. 1 . Space-filled models of selected mercuric conjugates and oxyanions implicated in molecular mimicry. Note the similarities in chemical structure between the cysteine (Cys) S-conjugate of methylmercury (CH 3 Hg-S-Cys) and the amino acid methionine. Also, note the similarities between the Cys S-conjugate of inorganic mercury (Cys-S-Hg-S-Cys) and amino acid cystine, and the homocysteine (Hcy) S-conjugate of inorganic mercury (Hcy-S-Hg-S-Hcy) of homocystine. A significant body of current evidence supports the hypothesis that mercuric conjugates of certain amino acids (such as Cys and Hcy) may act as molecular mimics of naturally occurring amino acids that are similar structurally to the mercuric complexes. Recent experimental findings from renal proximal tubular cells, transfected Madin-Darby canine kidney (MDCK) cells and oocytes from Xenopus laevis have demonstrated that Cys-S-Hg-S-Cys and Hcy-S-Hg-S-Hcy can act as molecular mimics of cystine and homocystine, respectively, at the sites of the luminal amino acid transporter, system b 0,+ and the basolateral organic anion transporter, OAT1. There is also evidence from cultured endothelial cells and Xenopus laevis indicating that CH 3 Hg-S-Cys can serve as a molecular mimic of the amino acid methionine at the site of system L, which can explain the movement of methylmercury across the endothelium of the bloodbrain barrier. There are also similarities in structure between monovalent phosphate and the oxyanionic forms of the toxic metals, arsenic (arsenate) or vanadium (vanadate) . Both arsenate and vanadate have been shown to mimic phosphate at the site of phosphate transporters. In addition, the structure of sulfate is shown in comparison with the structures of selenate, molybdate, and chromate, which are homologous to sulfate. There is evidence indicating that these oxyanions can mimic sulfate at the site of transporters responsible for its uptake.
value. Accordingly, no specific, dedicated mechanisms have evolved for their uptake, at least in most animal species. Yet, many studies have proven that these toxic metals do indeed gain entry into various target cells (for reviews, see Clarkson, 1993; Ballatori, 2002; Zalups, 2000a; Zalups and Ahmad, 2003) .
A number of different mechanisms for the transport of toxic metal species exist in the animal kingdom. In recent years, the concepts of molecular mimicry and ionic mimicry have been postulated as mechanisms by which certain toxic metal species can gain entry into target cells. The term, bmimicQ is defined by Webster's 3rd New International Dictionary of the English Language (2002) as a verb meaning bto copy or imitate very closely.Q Molecular mimicry refers to the phenomenon whereby the bonding of metal ions to nucleophilic groups on certain biomolecules results in the formation of organo-metal complexes that can behave or serve as a structural and/or functional homolog of other endogenous biomolecules or the molecule to which the metal ion has bonded ( Fig. 1 ; Ballatori, 2002; Clarkson, 1993; Zalups, 2000a) . Ionic mimicry, on the other hand, refers to the ability of an unbound, native, cationic species of a metal to mimic an essential element or cationic form of that element (Clarkson, 1993; Wetterhahn-Jennette, 1981; Zalups and Ahmad, 2003) . Molecular and ionic mimics may be classified as structural and/or functional mimics. A structural mimic refers to an elemental or molecular species that is similar in size and shape to another element or molecule. A functional mimic is one that can elicit the same effect (i.e., physiological response) as the native element or molecule. In the following sections, we discuss structural and functional mimicry in relation to molecular and/or ionic mimicry and the specific metal involved in these phenomena.
Molecular mimicry
It is thought that when metals bind to nucleophilic sites on certain biological molecules, the complexes formed are able to bmimicQ structurally and/or functionally endogenous substrates that normally bind to, or occupy, the active sites of carrier proteins, channels, structural proteins, enzymes, and/or transcription factors. In recent years, a number of carrier proteins have been implicated in the transport of some toxic metals. In particular, amino acid transporters (i.e., system b 0,+ , system L; Simmons-Willis et al., 2002 ) and organic anion transporters (i.e., OAT1 and OAT3; Aslamkhan et al., 2003; have been implicated in the absorptive transport of inorganic and organic forms of Hg in renal epithelial cells, endothelial cells and glial cells. Molecular mimicry has been implicated as the primary means for the entry of certain metals via these transporters. Interestingly, cationic forms of some metals can apparently mimic certain anionic complexes (i.e., oxyanions), as a form of molecular mimicry.
Ionic mimicry
In principle, ionic mimicry is similar to molecular mimicry. The term ionic mimicry has, for the most part, been used to describe the ability of an unbound, cationic species of a metal to behave or serve as a structural and/or functional homolog or mimic of another (usually an essential) element at the site of a carrier protein, ion channel, enzyme, structural protein, transcription factor and/or metal-binding protein. For example, a great deal of evidence has been accrued showing that the cationic species of certain toxic metals, such as Cd, can use ion channels (in particular calcium (Ca 2+ ) channels) and certain membrane transporters, such as the divalent metal transporter 1 (DMT1/DCT1/Nramp1), to gain access into target cells of mammalian organisms.
A considerable amount of scientific data on molecular and ionic mimicry has been published in recent years. Notwithstanding, numerous questions remain unanswered. This review will focus on known and putative mechanisms by which several toxic metals gain access to the intracellular compartments of target cells affected adversely by these metals. Evidence supporting the phenomena of molecular and/or ionic mimicry for selected toxic metals will be outlined individually by species of metal and the organs, tissues, and cells involved in the process.
Mercury
Hg is a unique toxic metal-pollutant that is found in many environmental and occupational settings. It can exist in elemental (metallic), inorganic, and/or organic forms. Elemental Hg (Hg 0 ) is unique among all metals in that it exists as a liquid at room temperature. Due to its high vapor pressure, Hg 0 can be released readily into the atmosphere as Hg vapor. Inorganic forms of Hg, as mercurous (Hg 1+ ) or mercuric (Hg 2+ ) ions, commonly combine with anionic species of chlorine, sulfur, or oxygen to form mercurous or mercuric salts. The primary cation of Hg found in environmental settings is the mercuric ion. Organic mercuric compounds form when mercuric ions bind covalently with carbon atoms of certain small organic functional groups such as methyl, ethyl, or phenyl groups. The most frequently encountered form of organic Hg in the environment is methylmercury (CH 3 Hg + ). It is formed primarily by methylation of inorganic mercuric ions by microorganisms in soil and water (reviewed in ATSDR, 2003a; Zalups, 2000a) .
All forms of Hg are toxic to almost all members of the animal kingdom. However, the extent of the adverse effects induced by Hg in an organism depends on the form of Hg at the time of exposure, the duration of exposure, and the route of exposure. Exposure to all forms of Hg, at least to some extent, has been shown to cause deleterious effects in the cardiovascular system (Carmignani et al., 1992; Soni et al., 1992; Warkany and Hubbard, 1953; Wakita, 1987) , gastrointestinal system (Afonso and deAlvarez, 1960; Bluhm et al., 1992; Lundgren and Swensson, 1949; Murphy et al., 1979) , liver (Jaffe et al., 1983; Murphy et al., 1979; Samuels et al., 1982) , kidneys (Murphy et al., 1979; Rowens et al., 1991; Samuels et al., 1982; Yasutake et al., 1991) , and neurological system (Jaffe et al., 1983; Kutsuna, 1968; Lin and Lim, 1993; Tsubaki and Takahashi, 1986) .
Unfortunately, the risk of humans being exposed to Hg is significant. Humans are not only exposed to Hg in numerous occupational and environmental settings, but they are also exposed to this toxic metal by dental amalgams and/ or medicinal and dietary sources (ATSDR, 2003a; Zalups, 2000a) . The majority of human exposure results from the ingestion of food and water contaminated with CH 3 Hg + .
Major predatory freshwater and saltwater fish, such as northern pike, salmon, swordfish and shark, can contain high levels of CH 3 Hg + , which is largely related to the longevity of fish in contaminated waters. Upon ingestion of contaminated muscular tissue of fish, CH 3 Hg + is released and absorbed by the gastro-intestinal tract of humans and other mammals (ATSDR, 2003a) . After entering systemic circulation, mercuric ions can then be delivered to target organs affected adversely by the metal.
It is important to note that within biological systems, mercurous or mercuric ions do not exist as inorganic salts, or in an unbound, bfreeQ ionic state (Hughes, 1957) . Mercuric ions have a very high affinity for thiol-containing biomolecules, such as glutathione (GSH), cysteine (Cys), homocysteine (Hcy), N-acetylcysteine (NAC), metallothionein (MT) and albumin. Thus, in biological systems, mercuric ions are always bound to one or more of these compounds. Several studies have shown that in the presence of excess low molecular weight, thiol-containing molecules, mercuric ions will bind to these molecules in a linear II, coordinate covalent manner ( Fig. 1; Canty et al., 1994; Fuhr and Rabenstein, 1973; Rubino et al., 2004) . Mercuric-thiol conjugates formed under these conditions appear to be stable in an aqueous environment from pH 1 to 14 (Fuhr and Rabenstein, 1973) . Furthermore, the formation constant for the thiol-Hg bond has been estimated to be as much as 10 orders of magnitude greater than the formation constant for the bonding of mercuric ions to other nucleophiles present in the same environment (reviewed by Zalups, 2000a) .
Numerous studies over the last 20 years have implicated some form of molecular mimicry in the uptake of thiolconjugates of inorganic and organic mercuric ions in selective target cells. Part of the impetus behind implicating molecular mimicry as a mechanism for the uptake of mercuric ions stems from the fact that mercuric conjugates of some non-protein thiols, such as Cys, Hcy, or GSH, are similar structurally to endogenous compounds such as cystine, homocystine, glutathione disulfide (GSSG), or methionine. Consequently, a number of investigators believe that selective mercuric species gain entry into certain target cells by serving as molecular mimics of these compounds at the sites of carrier proteins involved in the extracellular to intracellular transport of these biological molecules. Some of the most direct evidence implicating molecular mimicry in the transport of a toxic metal in a mammalian epithelial cell comes from studies of the transport of inorganic Hg (Hg 2+ ) in renal tubular epithelia.
Molecular mimicry and the renal transport of Hg

2+
The kidney is the primary target organ that takes up and accumulates Hg 2+ from the blood (reviewed by Zalups, 2000a) . The accumulation of this metal in the kidneys is very rapid, with as much as 50% of a nontoxic dose being present there within a few hours after exposure (Zalups, 1993) . Within the kidney, the segments of the proximal tubule are the principal portions of the nephron that take up and accumulate Hg 2+ . Until recently, the mechanisms by which Hg 2+ gains access to the intracellular compartment of renal tubular epithelial cells were largely unknown.
A number of theories regarding the transport of Hg 2+ into proximal tubular epithelial cells have been put forth over the years. One hypothesis postulates that some mercuric ions bound to albumin are taken up by endocytosis at the luminal plasma membrane of proximal tubular cells (Madsen, 1980; Zalups and Barfuss, 1993a) . Albumin is the most abundant protein in plasma and possesses a free SH group (Brown and Shockley, 1982) to which Hg 2+ can bind (reviewed by Zalups, 2000a) . As more information on the uptake of Hg 2+ along the proximal tubule has become available, it appears that Hg 2+ -albumin complexes are not the primary species of Hg taken up by proximal tubular epithelial cells.
Recent studies provide strong evidence indicating that there are at least two distinct mechanisms (or sets of mechanisms) responsible for the uptake of Hg in proximal tubular cells: at least one localized in the luminal membrane Zalups, 1995 Zalups, , 1997 Zalups, , 1998a Zalups, , 1998b Barfuss, 1993b, 1998a; Zalups and Minor, 1995; Zalups and Lash, 1997b; Zalups et al., 1991 Zalups et al., , 1998 and at least another one in the basolateral membrane (Aslamkhan et al., 2003; Zalups, 1995 Zalups, , 1997 Zalups, , 1998a Zalups and Barfuss, 1993b , 1998a Zalups and Lash, 1997b; Zalups and Minor, 1995; .
A large body of evidence has linked the preponderance of the luminal uptake of Hg 2+ in the proximal tubule to the actions of g-glutamyltransferase and cysteinylglycinase. Numerous in vivo experiments have demonstrated that inhibition of g-glutamyltransferase with acivicin (an irreversible alkylating agent of g-glutamyltransferase) reduces significantly the renal (proximal) tubular uptake and accumulation of systemically administered Hg 2+ (Bernt et al., 1985; de Ceaurriz et al., 1994; Tanaka et al., 1990; Tanaka-Kagawa et al., 1993; Zalups, 1995) . These studies led to the hypothesis that GSH S-conjugates of Hg 2+ (G-SHg-S-G), entering the luminal compartment of the proximal tubule, are degraded rapidly and efficiently by g-glutamyl-transferase and cysteinylglycinase to yield thiol S-conjugates of Hg 2+ , including Cys S-conjugates of Hg 2+ (Cys-S-Hg-SCys). Indeed, studies in brush-border membrane vesicles (isolated from the renal cortex and outer stripe of the outer medulla of rats) indicate that mercuric ions are taken up more readily when they are in the form of Cys-S-Hg-S-Cys than when they are in the form of G-S-Hg-S-G or mercuric conjugates of 2,3-dimercaptopropane-1-sulfonate (DMPS; Zalups and Lash, 1997b) . Moreover, studies in suspensions of rabbit proximal tubules (Wei et al., 1999; Zalups et al., 1993) and isolated perfused proximal tubules from rabbits (Cannon et al., 2000 (Cannon et al., , 2001 have provided additional evidence for the luminal uptake of Cys-S-Hg-S-Cys. Since this conjugate is similar structurally to the amino acid cystine, our laboratory hypothesized that Cys-S-Hg-S-Cys can serve as a mimic of cystine at the site of one or more transporters (of this amino acid) located in the luminal plasma membrane of proximal tubular epithelial cells. Subsequent experiments in isolated, perfused proximal tubules from rabbits provide substantive evidence that amino acid transporters are indeed involved in the luminal uptake of Cys-S-Hg-S-Cys (Cannon et al., 2001) . Evidence from these experiments indicates that there is at least one Na + -dependent and one Na + -independent carrier involved in the luminal transport of this conjugate along the proximal tubule.
Likely amino acid transporters involved in the Na + -dependent transport of Cys-S-Hg-S-Cys include systems B 0 , B 0,+ , and/or ASC. Direct evidence supporting the involvement of these specific carriers is currently lacking. One transporter that is most likely involved in the Na + -independent transport of Cys-S-Hg-S-Cys is system b 0,+ . This heterodimeric transporter, which is comprised of the subunits, b 0,+ AT, and 4F2hc (Palacin et al., 1998 , has a high affinity for cystine as well as neutral and basic amino acids. Recent direct molecular findings from type II MadinDarby canine kidney (MDCK) cells transfected stably with system b 0,+ indicate that this transport system can mediate the luminal uptake of Cys-S-Hg-S-Cys ( Fig. 2A ; . Analysis of substrate-specificity indicates that the uptake of Cys-S-Hg-S-Cys and cystine are inhibited by the same amino acids, meaning that these two molecular species are substrates for the same carrier, that is, system b 0,+ . Additional findings from the transfected cells indicate that this carrier does not readily transport mercuric conjugates of GSH (G-S-Hg-S-G), N-acetylcysteine (NAC-S-Hg-S-NAC), and cysteinylglycine (CysGly; CysGly-S-Hg-S-CysGly). The ability of system b 0,+ to transport Hcy S-conjugates of Hg 2+ (Hcy-S-Hg-S-Hcy) has also been tested recently in these transfected MDCK cells. Since Cys-S-Hg-S-Cys and Hcy-S-Hg-S-Hcy are structural homologs, we hypothesized that they both are substrates of the same transporter. In a separate study which utilized MDCK cells transfected with system b 0,+ , it was demonstrated that Hcy-S-Hg-S-Hcy is indeed a transportable substrate of system b 0,+ . Collectively, these data provide the most concrete lines of evidence supporting the hypothesis that Cys-S-Hg-S-Cys and Hcy-S-Hg-S-Hcy serve as molecular mimics of the amino acids cystine and homocystine, respectively, at the site of system b 0,+ . In addition to the uptake of Hg 2+ at the luminal plasma membrane, a preponderance of evidence indicates that approximately 40-60% of the proximal tubular uptake of Hg 2+ occurs via one or more transporters located at the basolateral membrane (Zalups, 1995 (Zalups, , 1997 (Zalups, , 1998a (Zalups, , 1998b Zalups and Barfuss, 1995 , 1998a , 1998b Zalups and Minor, 1995) . In experiments where the rates of glomerular filtration in rats were reduced to negligible levels, a 40% decrease in the renal tubular uptake of Hg 2+ was observed, indicating that the basolateral uptake of Hg 2+ comprises a significant fraction of the total renal uptake of Hg 2+ (Zalups and Minor, 1995) . Data from these experiments also demonstrated that the addition of para-aminohippurate (PAH), which is a specific inhibitor of the organic anion transporter (OAT) family (Ferrier et al., 1983; Pritchard, 1988; Roch-Ramel et al., 1992; Shimomura et al., 1981; Ullrich et al., 1987a Ullrich et al., , 1998b , effectively inhibited Hg 2+ uptake. These findings indicate that the majority of the basolateral uptake of Hg 2+ is likely mediated by one or more OATs, which are multispecific carriers that mediate the uptake of a wide variety of substrates (Wright and Dantzler, 2003) . Current evidence implicates only OAT1 and OAT3 in the uptake of Hg 2+ . Both of these transporters are localized in the basolateral plasma membrane of proximal tubular epithelial cells (Kojima et al., 2002; Motohashi et al., 2002) . The preponderance of current evidence indicates that OAT1 is the major mechanism for the uptake of Hg 2+ at the basolateral plasma membrane of proximal tubular cells (Zalups, 1995 (Zalups, , 1997 (Zalups, , 1998a (Zalups, , 1998b Zalups and Barfuss, 1995 , 1998a , 1998b Zalups and Lash, 1994; Zalups et al., 1998) .
Recent findings from MDCK cells (which normally do not express OAT1) that were stably transfected with OAT1 show that various mercuric conjugates, including Cys-S-Hg-S-Cys , NAC-S-Hg-S-NAC (Aslamkhan et al., 2003) , and Hcy-S-Hg-S-Hcy are substrates of this transporter (Fig. 2B ). OAT1 and OAT3 have also been implicated in the transport of Cys-S-Hg-S-Cys in oocytes from Xenopus laevis altered at a molecular level to express these two transporters (Aslamkhan et al., 2003; . A significant -independent transporter comprised of a heavy chain and a light chain, which are linked together by a disulfide bond (S-S). The light chain, b 0,+ AT (blue cylinders), possesses 12 transmembrane domains, while the heavy chain, rBAT (red cylinder), traverses the plasma membrane only once. This carrier is localized in the luminal plasma membrane of transporting epithelia (such as renal proximal tubular epithelial cells) and functions as an amino acid exchanger that mediates the transport of cystine as well as a variety of neutral and cationic amino acids. Recent studies have identified additional substrates for this carrier, including mercuric conjugates of cysteine (Cys; Cys-S-Hg-S-Cys) and homocysteine (Hcy; Hcy-SHg-S-Hcy), which are similar structurally to the amino acids cystine and homocystine, respectively. Experiments carried out in Madin-Darby canine kidney (MDCK) cells transfected stably with both subunits of system b 0,+ showed that Cys-S-Hg-S-Cys and Hcy-S-Hg-S-Hcy mimic cystine and homocystine, respectively, at the site of this transporter. (B) The organic anion transporter 1 is a multi-specific carrier that is localized in the basolateral plasma membrane of many types of epithelial cells. Its expression is especially pronounced in renal proximal tubular epithelial cells. This transporter spans the plasma membrane 12 times and has two large intracellular loops, with the first between the first and second transmembrane domains and the second joining the sixth and seventh domains. The inward transport of organic anions is driven by the outward flux of a-ketoglutarate (a-KG). Data from recent studies in which MDCK cells were transfected stably with OAT1 demonstrate that mercuric conjugates of N-acetylcysteine (NAC-S-Hg-S-NAC), Cys-S-Hg-S-Cys, and Hcy-S-Hg-S-Hcy are transportable substrates of this carrier. As hypothesized for system b 0,+ , these mercuric species likely act as molecular mimics of endogenous substrates of OAT1.
body of recent molecular evidence indicates that the mercuric conjugates of Cys, Hcy, and NAC are taken up via a mechanism involving molecular mimicry.
Molecular mimicry and the intestinal transport of Hg
2+
Gastrointestinal absorption of Hg 2+ , although inefficient, occurs following consumption of food and/or liquids contaminated with inorganic forms of Hg. Thus, understanding the intestinal absorption, accumulation, and excretion of Hg 2+ is important. Foulkes (2000) suggested that the uptake of Hg 2+ from the lumen of the intestine is dependent upon the composition of the contents in the intestinal lumen. In other words, the mechanism(s) by which Hg 2+ is transported is/are dependent upon the ligands to which Hg 2+ is bound. Food that is digested in the stomach and small intestine contains a great number of thiol-containing molecules, such as amino acids and peptides, to which Hg 2+ may bind. Given the prevalence of amino acid and peptide transporters in enterocytes lining the three segments of the small intestine (Dave et al., 2004; Ganapathy et al., 2001) , it is reasonable to hypothesize that Hg 2+ may be taken up by one or more of these carriers. Inasmuch as ingested Hg 2+ likely forms complexes with thiol-containing molecules in the lumen of the small intestine, these complexes may serve as structural or functional mimics of some of the endogenous molecules, such as amino acids and/or polypeptides, which are absorbed along the small intestine. Surprisingly, even though the intestine appears to be the initial site of Hg 2+ absorption, very little is known about the mechanisms involved in the gastrointestinal handling of this metal.
In vivo studies, in which sections of rat duodenum, jejunum, ileum and stomach were perfused with HgCl 2 for various time intervals, demonstrated that the duodenum is the primary site of Hg 2+ absorption within the gastrointestinal tract of rats (Endo et al., 1984) . Interestingly, in rats with ligated bile ducts, the absorption of Hg 2+ was decreased significantly. Subsequent co-administration of bile and HgCl 2 increased the absorption of Hg 2+ in the duodenum to levels similar to those observed in control rats. Furthermore, it was shown that the accumulation of Hg 2+ in the cells of the small intestine was greatest when the pH of the perfusion solution was 4.7 (Endo et al., 1984 (Endo et al., , 1986 . In contrast, when the pH of the perfusion solution was 8.0, the accumulation of Hg 2+ in the intestine was significantly lower than that at pH 4.7. This difference in accumulation may be due to an increase in the absorptive transport of Hg 2+ from the intestinal lumen into the blood. Accordingly, the content of Hg 2+ in blood was the highest when the perfusion solution was more alkaline (pH 8.0). These data suggest that alkalinity increases the absorption of Hg 2+ across the intestine; however, they do not implicate a specific mechanism in this process. Foulkes and Bergman (1993) Laporte et al., 2002) . It is likely that amino acids and peptides present in digested food bind to Hg 2+ and that the complexes formed are taken up by active and/or facilitated mechanisms involving amino acid and/or peptide transporters. Owing to the fact that amino acid transporters have been implicated in the transport of Cys-SHg-S-Cys in renal proximal tubular cells, and the prevalence of amino acid transporters in the luminal plasma membrane of enterocytes, it seems reasonable to postulate that a similar mechanism plays a role in the intestinal absorption of Hg 2+ . However, direct evidence supporting such a mechanism has yet to be provided.
The intestine also plays an important role in the elimination of Hg 2+ . Two mechanisms appear to be involved in the fecal elimination of Hg 2+ : (1) transcellular and/or paracellular secretion of Hg 2+ via enterocytes, and (2) delivery of Hg 2+ into the intestinal lumen via bile (Zalups and Lash, 1994) . Data from in vivo studies in rats with cannulated or ligated (Zalups, 1998c) bile ducts indicate that intestinal secretion of Hg 2+ from the blood into the lumen of the intestine accounts for a substantial fraction of the total pool of Hg 2+ that is excreted in the feces. Up until these studies, it had been assumed that biliary secretion of Hg 2+ was the principal mechanism involved in the fecal elimination of systemic Hg 2+ . The intestinal secretion of Hg 2+ may involve the transport of an Hg 2+ -thiol complex, which could act as a mimic or a structural homolog of an endogenous molecule normally secreted by enterocytes. Amino acid transporters are potential mechanisms for this secretion. Given that many of these transporters are actually counter-exchangers, they have the potential to transport substrates both into and out of cells. Consequently, Hg 2+ -thiol complexes, such as Cys-S-Hg-S-Cys, may utilize these carriers to enter and exit enterocytes.
Molecular mimicry and the hepatic transport of Hg
2+
The transport of Hg 2+ across the sinusoidal membrane into hepatocytes is not well defined. Hepatocytes contain some of the same transporters that have been implicated in the transport of Hg 2+ in other organs, including a transporter of GSSG and numerous amino acid carriers. Therefore, it can be postulated that these transporters may be involved in the uptake of Hg 2+ across the sinusoidal membrane of the hepatocytes. It has been established that Hg 2+ forms complexes with GSH and/or amino acids, such as Cys and Hcy. Although transporters for GSSG (multidrug resistance proteins 1 and 2) have been identified in the canalicular membrane (Akerboom et al., 1984 (Akerboom et al., , 1991 Keppler et al., 1998; Leslie et al., 2001 ), they have not been localized in the sinusoidal membrane. Furthermore, various amino acid carriers have been identified in the liver (Bode, 2001; Wagner et al., 2001) ; however, it is presently unclear whether these carriers are present on the sinusoidal membrane.
Much more information is available on the transport of Hg 2+ across the canalicular plasma membrane of hepatocytes. Several studies have provided important data regarding potential mechanisms involved in the hepatocellular export of Hg 2+ across the canalicular membrane. The prevailing theory regarding this export implicates a mechanism by which the transport of Hg 2+ is dependent on the cytosolic concentration of GSH (Ballatori and Clarkson, 1983 , 1985a , 1998b Dutczak and Ballatori, 1992) . Subsequent in vivo studies, in which hepatocellular concentrations of GSH were reduced with pretreatment with buthionine sulfoximine (BSO) or diethylmaleate (DEM), offer additional evidence supporting the role of GSH for the transport of Hg 2+ into the canalicular compartment (Zalups and Lash, 1997a ). It appears that in the absence of adequate levels of cytosolic GSH, mercuric ions are unable to exit the hepatocyte, which leads to increased cytosolic accumulation of Hg 2+ . Though the actual mechanism(s) responsible for the transport of mercuric ions from within hepatocytes across the canalicular plasma membrane has/have not been demonstrated directly, experimental evidence indicates that Hg 2+ bonds GSH to form G-S-Hg-S-G, which appears to be transported into the biliary canalicular compartment. Since G-S-Hg-S-G is similar structurally to GSSG, this mercuric complex may serve as a molecular mimic of GSSG at the site of a GSSG transporter. However, a definitive role for a transporter of GSSG in the transport of Hg 2+ has yet to be elucidated. This transporter may be one of the multiple drug resistance proteins (MRPs), which apparently mediate the transport GSH S-conjugates (Leslie et al., 2001; Suzuki and Sugiyama, 1998) .
Transport of Hg 2+ in placenta
Normally, very little Hg 2+ enters and accumulates in the placenta (Ask et al., 2002; Inouye and Kajiwara, 1990; Suzuki et al., 1967) , and the mechanism(s) that mediate placental uptake of Hg 2+ are poorly understood. Interestingly, experiments in brush-border membrane vesicles from human placenta suggest that an amino acid transporter may be involved in the uptake of Hg 2+ in this organ (Iioka et al., 1987) . These experiments demonstrated that the Na + -dependent uptake of alanine was inhibited significantly by HgCl 2 , indicating that one or more amino acid transporters may be involved in this uptake. As these studies used HgCl 2 rather than an Hg-thiol complex, such as Cys-S-Hg-S-Cys, the results may not reflect accurately physiological processes that occur in vivo. They do provide, however, valuable preliminary data. Based on these data and the prevalence of amino acid transporters in the placenta (Jansson, 2001; Kudo and Boyd, 2002) , we can postulate that Hg 2+ , as a thiolconjugate, mimics a structurally similar amino acid and is utilized as a substrate by one or more amino acid transporters. This proposed mechanism of molecular mimicry may be similar to that demonstrated in other tissues (e.g., system b 0,+ in proximal tubular cells, system L in endothelial and glial cells of the blood-brain barrier).
Intracellular mimicry of Hg
2+
Just as some Hg-thiol complexes can mimic endogenous molecules at the site of proteins present in the plasma membrane, these complexes may also mimic molecules at the binding site(s) of intracellular proteins and enzymes. Owing to the fact that Cys-S-Hg-S-Cys mimics cystine at the site of an amino acid transporter on the plasma membrane , it is not surprising to find that this conjugate also acts as a mimic of this amino acid at binding sites of intracellular molecules that utilize cystine as a substrate. An example of this mimicry has been demonstrated by the preliminary findings of Cooper et al. (2004) , which indicate that Cys-S-Hg-S-Cys acts as a mimic of cystine at the binding site of the intracellular enzyme, gcystathionase. This enzyme is activated normally by the binding of cystine or cystathionine. As the binding of Cys-S-Hg-S-Cys was shown to inactivate the enzyme, rather than activate it, it can be concluded that this conjugate is behaving as a structural, but not a functional, mimic of cystine and cystathionine. These findings suggest that the ability of molecular species of metals to mimic endogenous molecules may have serious, deleterious effects on intracellular processes.
Molecular mimicry and the transport of CH 3 Hg + in brain
The brain and central nervous system (CNS) are the primary target sites where the adverse affects of CH 3 Hg + are manifested (ATSDR, 2003a,b; WHO, 2000) . Accordingly, a great number of studies have focused on mechanisms by which this organic form of Hg gains access to the CNS, and more specifically, how it crosses the blood-brain barrier. As with inorganic mercuric ions, the methyl mercuric ion (CH 3 Hg + ) does not exist as a free, unbound cation in biological systems (Hughes, 1957) , but rather, is found conjugated to thiol-containing biomolecules, such as GSH, Cys, Hcy, or NAC (reviewed by Clarkson, 1993) . In fact, initial studies utilizing homogenates of rat cerebrum demonstrated that the primary non-protein thiol bound to CH 3 Hg + is GSH (Thomas and Smith, 1979) . Subsequent studies in rats and primary cultures of bovine brain endothelial cells revealed a possible role for Cys in the transport of CH 3 Hg + across the blood-brain barrier (Hir-ayama, 1980; Clarkson, 1988, 1989) . In particular, co-administration of Cys with CH 3 Hg + has been shown to increase the uptake of CH 3 Hg + into capillary endothelial cells of the blood-brain barrier. Interestingly, experiments in rats demonstrated that the uptake of CH 3 Hg + is inhibited significantly by the neutral amino acid, phenylalanine (Hirayama, 1980 (Hirayama, , 1985 Thomas and Smith, 1982) . The data from these experiments led to the hypothesis that the Cys S-conjugate of CH 3 Hg + (CH 3 Hg-S-Cys) is a transportable substrate of a neutral amino acid transporter in the capillary endothelium of the blood-brain barrier. In vivo studies in rat brain (Aschner and Clarkson, 1988) and in vitro studies in bovine cerebral capillary endothelial cells (Aschner and Clarkson, 1989) demonstrated that the uptake of CH 3 Hg-S-Cys is inhibitable by neutral amino acids, providing additional support for the theory that this complex is taken up by a neutral amino acid carrier. The investigators in these studies suggested that CH 3 Hg-S-Cys behaves as a bmimicQ of an amino acid in order to cross the blood-brain barrier. Indeed, it is similar structurally to the amino acid methionine (Jernelov, 1973; Landner, 1971) , which is a substrate of the neutral amino acid carrier, system L.
System L is present in the basolateral plasma membrane of many types of transporting epithelia. Interestingly, in the endothelial cells lining the blood-brain barrier, this carrier is found in both the apical and basolateral plasma membranes (Betz and Goldstein, 1978) . Not surprisingly, system L is considered a major carrier of large neutral amino acids into the substance of the brain. In addition, this transporter has a broad substrate-specificity (Oldendorf, 1973) , which may allow it to utilize CH 3 Hg-S-Cys as a substrate. Indeed, in vivo studies in rats (Kerper et al., 1992) and in vitro studies utilizing primary cultures of rat astrocytes (Aschner et al., 1990 (Aschner et al., , 1991 provided evidence that CH 3 Hg-S-Cys is a transportable substrate of system L. The involvement of this transporter in the uptake of CH 3 Hg-S-Cys was also demonstrated in another study utilizing cultured endothelial cells from the brain (Mokrzan et al., 1995) . Interestingly, this study measured the uptake of CH 3 Hg + , as a conjugate of Hcy (CH 3 Hg-S-Hcy), or as CH 3 Hg-S-Cys and found that these two complexes were transported similarly. Though the authors of this study suggest that system L is involved in the uptake of CH 3 Hg-S-Cys, they did not conclude that this carrier also mediates the uptake of CH 3 Hg-S-Hcy. Fig. 3 . Schematic representation of the transport of methylmercuric conjugates of cysteine (Cys; CH 3 Hg-S-Cys) by the amino acid transporter system L in the capillary endothelium of the blood-brain barrier. System L is a heterodimeric transporter that has been shown to mediate the Na + -dependent transport of a variety of large, neutral amino acids, including methionine, phenylalanine, leucine, and isoleucine. This transporter is an amino acid exchanger whose activity is dependent on the disulfide linkage (S-S) between the heavy chain 4F2hc and a light chain LAT1 or LAT2. System L has been identified in the basolateral plasma membranes of numerous types of transporting epithelia. Interestingly, it has been localized in the apical and basolateral plasma membranes of the endothelial cells lining the blood-brain barrier. Moreover, system L has been shown recently to take up and transport CH 3 Hg-S-Cys across this endothelial lining. Inasmuch as CH 3 Hg-S-Cys is similar structurally to the amino acid methionine, it has been suggested that this conjugate acts as a molecular mimic of methionine at the site of system L.
Since these initial studies, two isoforms of the system L family have been identified at the molecular level: the Ltype, large neutral amino acid transporters, LAT1 (Kanai et al., 1998; Prasad et al., 1999) , and LAT2 (Pineda et al., 1999) . These transporters are heterodimeric proteins, comprised of a heavy chain, 4F2hc, and a light chain, LAT1 or LAT2, bound together by a disulfide bond (reviewed by Chillaron et al., 2001) . With this knowledge, it has become possible to identify and characterize further the specific mechanisms involved in the uptake of CH 3 Hg-S-Cys. To illustrate this point, Simmons-Willis et al. (2002) utilized oocytes from Xenopus laevis to study directly the involvement of LAT1 and LAT2 in the transport of this conjugate. These investigators provided the first line of direct molecular evidence implicating CH 3 Hg-S-Cys as a transportable substrate of LAT 1 and 2 (Simmons- . These data also provide substantive evidence for the phenomenon of molecular mimicry, where CH 3 Hg-S-Cys appears to mimic methionine at the site of system L (Fig. 3 ).
Molecular mimicry and the renal transport of CH 3 Hg +
Though the primary target of CH 3 Hg + is the central nervous system, it also induces significant detrimental effects in other organs, including the kidneys (Friberg, 1959; Prickett et al., 1950; Clarkson, 1970a, 1970b; Magos and Butler, 1976; Magos et al., 1981 Magos et al., , 1985 McNeil et al., 1988; Zalups et al., 1992) . Until recently, it was unclear as to how this organo-metal complex is taken up by renal tubular epithelial cells. Richardson and Murphy (1975) demonstrated that the renal tubular uptake of CH 3 Hg + is dependent upon the cellular concentration of GSH. Moreover, several studies have shown that when CH 3 Hg + is co-administrated with GSH, the renal uptake and accumulation of CH 3 Hg + increases (Alexander and Aaseth, 1982; Tanaka et al., 1992) .
It has been proposed that g-glutamyltransferase and cysteinylglycinase, which are present in abundance on the luminal (brush-border) plasma membrane of proximal tubular cells, act upon GSH S-conjugates of CH 3 Hg + (CH 3 Hg-S-G) to yield CH 3 Hg-S-Cys (reviewed by Zalups, 2000a) . In vitro evidence indicates that the methyl mercuric ion remains bonded to the sulfur atom of Cys during the catabolism of GSH (Naganuma et al., 1988) . Experimental evidence supporting the role of g-glutamyltransferase in the renal tubular uptake of CH 3 Hg + comes from studies in which the activity of this enzyme was inhibited by the alkylating agent acivicin. Following the pretreatment with acivicin, the renal tubular uptake of CH 3 Hg + was shown to decrease while the urinary excretion of GSH and CH 3 Hg + was shown to increase (Bernt et al., 1985; de Ceaurriz and Ban, 1990; DiSimplicio et al., 1990; Gregus et al., 1987; Mulder and Kostyniak, 1985; Naganuma et al., 1988; Tanaka et al., 1990 Tanaka et al., , 1991 Tanaka et al., , 1992 . The observed changes in the renal cellular uptake and excretion of CH 3 Hg + indicate that the catabolism of the CH 3 Hg-S-G complex is a necessary step in the renal proximal tubular absorption of CH 3 Hg + . Findings from some studies indicate that a fraction of the CH 3 Hg + that enters into systemic circulation is oxidized to Hg 2+ either before and/or after it enters the proximal tubular epithelial cells of the kidney (Dunn and Clarkson, 1980; Gage, 1964; Clarkson, 1970a, 1970b; Omata et al., 1980; Zalups et al., 1992) . These findings lead one to suggest that some or all of the mercuric ions taken up in the kidneys after exposure to CH 3 Hg + may be due to the transport of some chemical form of Hg 2+ rather than CH 3 Hg + . Tanaka et al. (1992) demonstrated in mice the existence of one or more luminal and basolateral mechanisms involved the renal tubular uptake of CH 3 Hg + . These investigators found that the luminal mechanism(s) are greatly dependent upon the actions of g-glutamyltransferase. The role of cysteinylglycinase, however, was not studied. Collectively, their data indicate that the species of CH 3 Hg + taken up is most likely in the form of a cysteinylglycine S-conjugate of CH 3 Hg + (CH 3 Hg-SCysGly) or CH 3 Hg-S-Cys. The mechanism(s) responsible for the uptake of CH 3 Hg-S-Cys in the proximal tubule has/ have not yet been identified. However, we can draw parallels from the information available for the transport of Hg 2+ , as Cys-S-Hg-S-Cys. Inasmuch as Cys-S-Hg-S-Cys appears to mimic cystine at the site of an amino acid transporter in proximal tubular cells , it is possible that CH 3 Hg-S-Cys behaves in a similar way. Additionally, since CH 3 Hg-S-Cys has been implicated as a molecular mimic of methionine at the site of system L in endothelial and glial cells, this complex may also mimic methionine at the site of one or more carriers of this amino acid in the kidney.
Uptake of CH 3 Hg + at the basolateral membrane may also involve a multi-specific carrier, such as the organic anion transporter 1 (OAT1). As mentioned above, in the kidneys, this transporter is localized exclusively in the basolateral membrane of proximal tubular epithelial cells (Kojima et al., 2002; Motohashi et al., 2002) . There is some evidence from studies in Xenopus laevis oocytes implicating this transporter in the cellular uptake of NAC and DMPS Sconjugates of CH 3 Hg + (CH 3 Hg-S-NAC and (CH 3 Hg-S) 2 -DMPS, respectively; Koh et al., 2002) . Thus, CH 3 Hg-S-Cys may also be taken up at the basolateral membrane of proximal tubular epithelial cells by OAT1.
The mechanism(s) by which CH 3 Hg + is transported out of the proximal tubular cell into the tubular lumen have not been tested directly. However, Koh et al. (2002) proposed that the efflux of CH 3 Hg + across the luminal plasma membrane is mediated by MRP2. MRP2 is an ATP-binding cassette (ABC) transport protein that is localized in the luminal membrane of the proximal tubule (Schaub et al., 1997 (Schaub et al., , 1999 and has been shown to be involved in the transport of glutathione-S conjugates of other metals (Leslie et al., 2004) . Clearly, a great deal about this potential mechanism remains to be clarified.
Molecular mimicry and the transport of CH 3 Hg + in placenta
One of the most publicized and serious toxicological consequences of CH 3 Hg + exposure is the deleterious neurological effects observed in fetuses whose mothers were exposed to this metal during pregnancy (Amin-Zaki et al., 1974; Harada, 1978 Harada, , 1995 Inouye and Kajiwara, 1988; Inouye, 1986, 1992; Matsumoto et al., 1965) . CH 3 Hg + crosses the placenta readily and accumulates in the fetus (Inouye and Kajiwara, 1988; Inouye et al., 1985; Suzuki et al., 1967) and placenta (Ask et al., 2002) at levels higher than that in maternal tissues and blood. Yet, little is known about the mechanism(s) by which this metal is taken up and transported across this organ. Kajiwara et al. (1996) showed that CH 3 Hg + is transported across the rat placenta by a neutral amino acid carrier in a time-and dosedependent manner. These investigators demonstrated that co-injection with methionine increased the uptake of CH 3 Hg + . In addition, they proposed that this increase might be the result of the intracellular conversion of methionine to Cys, which may subsequently combine with CH 3 Hg + to form the readily transportable conjugate, CH 3 Hg-S-Cys. This conjugate may then mimic methionine at the site of system L to gain access to the placenta. Accordingly, the authors concluded that the neutral amino acid carrier, system L (Kajiwara et al., 1996) , mediated the uptake of CH 3 Hg + in placenta. The exact species of CH 3 Hg + that was transported was not determined in this study, nor was there direct evidence supporting the conclusion that system L was involved in this transport. However, since system L has been shown to mediate the transport of CH 3 Hg-S-Cys across the epithelial cells of and the astrocytes associated with the blood-brain barrier (Aschner et al., 1990; Kerper et al., 1992; Mokrzan et al., 1995) , it is feasible that this same carrier is also responsible for the uptake of CH 3 Hg-S-Cys in placenta. System L has been identified in the placenta (Kanai et al., 1998; Pineda et al., 1999; Prasad et al., 1999) and is an important participant in the transfer of nutrients from the maternal to the fetal circulation.
It is important to note that a number of other protein carriers have been identified in the placenta. These include MRPs, organic anion-transporting polypeptides (OATPs), OATs, organic cation transporters (OCTs), and zinc transporters (Leazer and Klaassen, 2003) . The localization of most of these transporters in the placental membrane has not been determined. However, one can suggest that one or more of them may play a role in the uptake and/or efflux of CH 3 Hg + -complexes. Interestingly, MRP1, 2, and 3 have been identified in the apical membrane of the syncytiotrophoblast. MRP1 and MRP3 were also present in the endothelial cells of placental blood vessels (St. Pierre et al., 2000) . Given the role of MRPs in detoxification (Leslie et al., 2001) , it is logical to hypothesize that these carriers mediate the efflux of unwanted substances from the fetal circulation. Thus, in cases of CH 3 Hg exposure, some of the CH 3 Hg may be transported back across the placenta into the maternal circulation.
Molecular mimicry and the intestinal transport of CH 3 Hg + Ingestion of food and water contaminated with CH 3 Hg + is the primary route of human exposure to this compound. Thus, a thorough understanding of the mechanisms involved in the intestinal absorption of CH 3 Hg + is an important determinant of understanding the transport and toxicity of CH 3 Hg + in the body. Studies in ligated rat intestinal segments demonstrated that the uptake of CH 3 Hg-S-Cys and CH 3 Hg-S-CysGly was 1.5 times greater than the uptake of CH 3 Hg-S-G (Urano et al., 1990) . Interestingly, when the activity of g-glutamyltransferase in the striated border of the intestine was inhibited by acivicin, the uptake of CH 3 Hg + (when presented as CH 3 Hg-S-G) in the enterocytes was reduced by 50%. These data indicate that CH 3 Hg-S-Cys and/or CH 3 Hg-S-CysGly is/are the most likely species of CH 3 Hg + taken up at the luminal plasma membrane of enterocytes. Since the luminal plasma membrane of enterocytes contains dehydropeptidases, a fraction of CH 3 Hg-SCysGly formed in the lumen is likely degraded to yield CH 3 Hg-S-Cys. Any CH 3 Hg-S-CysGly that escapes degradation, however, may be transported by a peptide transporter present in the luminal membrane. In the intestine, di-and tripeptide transport is the primary means for the uptake of amino acids. Given this, and the similarity between CH 3 Hg-S-CysGly and a small peptide, it is possible that this complex mimics an endogenous di-or tripeptide to gain access to enterocytes. In addition, CH 3 Hg-S-Cys has been identified as the primary species of CH 3 Hg + that is delivered into lumen of the intestine by bile. Once in the lumen, CH 3 Hg-S-Cys is reabsorbed rapidly by the enterocytes possibly by acting as a mimic of methionine at the site of an amino acid carrier (Ballatori et al., 1998; Dutczak and Ballatori, 1992; Norseth and Clarkson, 1971; Wang et al., 2000) present in the luminal plasma membrane. Indeed, the findings from a recent in vitro study of isolated, perfused catfish intestines, indicate that system L mediates at least some of the luminal transport of CH 3 Hg-S-Cys in enterocytes (Leaner and Mason, 2002) . The investigators in this study suggested that there is/are one or more activetransport carrier proteins involved in this uptake. Competitive inhibition experiments provided indirect evidence that a neutral amino acid transporter, possibly system L, mediates (at least some of) the uptake of CH 3 Hg-S-Cys in intestinal enterocytes.
Additional data from experiments in ligated segments of rat intestine have demonstrated that treatment with probenecid (an inhibitor of OAT1), in addition to acivicin, significantly reduced the luminal uptake of CH 3 Hg + (as CH 3 Hg-S-G; Urano et al., 1990) . It was concluded that there are two independent transport systems for the uptake of CH 3 Hg + across the luminal plasma membrane of enterocytes. One of these mechanisms is dependent upon the activity of g-glutamyltransferase, while the other appears to be inhibited by probenecid. These findings lead one to postulate that one or more OATs may also be involved in the intestinal uptake of CH 3 Hg + . It is important to note, however, that probenecid is not a specific inhibitor of OAT, and may act upon other transporters. Furthermore, there is currently no direct evidence to suggest that OATs are present in the intestine.
The efflux of CH 3 Hg + across the basolateral membrane of the enterocyte into the extracellular compartment is less clear than the luminal transport of this molecule. Foulkes (1993) suggested that the intracellular concentrations of GSH play a role in regulating the efflux of CH 3 Hg + out of the intestine, although data supporting this notion are lacking. The apparent similarities between the structures of CH 3 Hg-S-G and GSH may lead one to postulate that this conjugate is a transportable substrate of a GSH transporter present in the basolateral plasma membrane of enterocytes, which would facilitate its transport into blood.
Molecular mimicry and the hepatic transport of CH 3 Hg + After CH 3 Hg + is absorbed by the intestine, it is delivered to the liver via portal blood. Although, little is known about the mechanisms involved in the hepatocellular uptake of CH 3 Hg + from sinusoidal blood, the data from an in vivo study in rodents showed that the uptake and accumulation of CH 3 Hg + are enhanced after co-administration of or subsequent administration with Cys or GSH (Thomas and Smith, 1982) . These data also indicate that CH 3 Hg-Cys is the most likely species of CH 3 Hg + taken up at the sinusoidal membrane of hepatocytes (Thomas and Smith, 1982) . Overall, these findings are consistent with the notion that an amino acid transporter, such as system L is involved in this uptake.
The current evidence indicates that the transport of CH 3 Hg + from the hepatocytes into the biliary canaliculus is dependent on GSH (Ballatori and Clarkson, 1982 , 1983 , 1985a , 1998b Refsvik, 1982; Refsvik and Norseth, 1975) . Indeed, early studies in hepatic tissues indicate that the preponderance of CH 3 Hg + within hepatocytes is bound to GSH (Omata et al., 1978) . Magos et al. (1978) demonstrated that increasing hepatic levels of GSH enhanced the biliary excretion of GSH and CH 3 Hg + . In contrast, Refsvik (1978) showed that compounds that reduce significantly the hepatic and biliary levels of GSH cause the accumulation of CH 3 Hg + in the liver to decrease. It appears that the intracellular concentration of GSH has a significant effect on the transport of CH 3 Hg + . Indeed, studies in mice deficient in g-glutamyltransferase have demonstrated that the distribution and accumulation of CH 3 Hg + in liver is affected by the actions of gglutamyltransferase and cysteinylglycinase (Ballatori et al., 1998) . Furthermore, experiments in cultured human hepatocytes (HepG2 cells) in which g-glutamyltransferase was inhibited indicate that the transport of CH 3 Hg + in these cells is dependent upon the intracellular concentration of GSH (Wang et al., 2000) . One can hypothesize that CH 3 Hg-S-G is formed within the hepatocytes and is subsequently transported into the bile at the canalicular membrane. It is reasonable to hypothesize that CH 3 Hg-S-G may act as a mimic of GSH at the site of a GSH transporter in the canalicular membrane of hepatocytes. Accordingly, Dutczak et al. (1993) have suggested that a GSH transport system on the canalicular membrane serves a primary role in the biliary secretion of CH 3 Hg-S-G. A GSH-transporter has since been identified on the canalicular membrane of hepatocytes (Ballatori and Dutczak, 1994; Ballatori and Truong, 1995; Fernandez-Checa et al., 1992 Garcia-Ruiz et al., 1992) and it most likely plays a crucial role in the export of CH 3 Hg + . After being secreted into the bile, CH 3 Hg + may be reabsorbed along the biliary tree as a conjugate of GSH or one of its metabolites, CysGly, and/or Cys (reviewed by Ballatori, 1994) . Experimental evidence indicates CH 3 Hg + is absorbed more readily by ductal epithelial cells when it is administered as a complex of GSH or Cys (Dutczak et al., 1991) . Once in the biliary tree, CH 3 Hg-S-G appears to be catabolized to yield CH 3 Hg-S-Cys, which can be reabsorbed by cells lining the bile ducts and the enterocytes in the intestine (Dutczak and Ballatori, 1992) . Though the actual mechanism(s) involved in this uptake have yet to be determined, it is reasonable to hypothesize that CH 3 HgCys acts as a mimic of an amino acid at the site of an amino acid transporter, such as system L. A number of amino acid transporters, including system L (LAT3; Babu et al., 2003) , have been identified in the liver (Bode, 2001; Wagner et al., 2001) ; however, the exact localization of any one of them has not yet been determined.
Molecular mimicry and the transport of CH 3 Hg + in erythrocytes
Studies of the uptake of CH 3 Hg + , as CH 3 Hg-S-G, in erythrocytes have provided additional information regarding the cellular handling of this conjugate. Experiments carried out at 5 8C, indicated that the following systems were involved in this transport: (1) one or more OATs, which appear to be the primary mechanism of uptake, (2) a dglucose diffusive transporter, (3) a cysteine facilitated transporter, and (4) a Cl À transporter (Wu, 1995) . Based on these findings, it appears that CH 3 Hg-S-G mimics an endogenous substrate of each of these transporters in order to gain access into the erythrocyte. In later studies, Wu (1996) measured the uptake of CH 3 Hg-S-G at 5 8C and 20 8C and concluded that an OAT is the primary mechanism of CH 3 Hg-S-G uptake at both temperatures. Additional studies in which probenecid inhibited the uptake of CH 3 Hg-S-G confirmed previous data indicating that this conjugate is a transportable substrate of OAT (Wu, 1997) . These data support the hypothesis that molecular mimicry at the site of one or more transporters plays a role in the transport of CH 3 Hg-S-G in erythrocytes.
Cadmium
Cd is a naturally occurring group IIB element found in the earth's crust. The ionic form of Cd (Cd 2+ ) is usually combined with ionic forms of oxygen (cadmium oxide, CdO), chlorine (cadmium chloride, CdCl 2 ), or sulfur (cadmium sulfate, CdSO 4 ). Approximately 30,000 tons of Cd are released into the atmosphere each year, with an estimated 4000 to 13,000 tons coming from human activities. Since Cd 2+ does not break down in the environment, the risk of human exposure is increasing constantly (ATSDR, 2003b) .
Humans are exposed to Cd 2+ primarily through the ingestion of contaminated food or water and the inhalation of cigarette smoke. Major sources of dietary Cd 2+ are fish, liver, grains, leafy vegetables, potatoes, and other root vegetables. On average, a person in the United States will consume approximately 30 Ag of Cd 2+ per day, with 1-3 Ag of that absorbed by the gastrointestinal tract. Of a more serious nature is the inhaled Cd 2+ from cigarette smoke, which is primarily in the form of CdO, (ATSDR, 2003b; Oberdorster, 1992) . Each cigarette contains approximately 1-2 Ag of Cd 2+ , with 40-60% of that being absorbed through the lungs directly into the systemic circulation (ATSDR, 2003b; Elinder et al., 1976; Lewis et al., 1972) . Exposure to Cd 2+ on a chronic basis can cause adverse affects in the kidneys, liver, lung, pancreas, testis, placenta, and bone (ATSDR, 2003b; Bhattacharyya et al., 2000; Diamond and Zalups, 1998; Friberg et al., 1986; Goyer et al., 1984; Habeebu et al., 1998; Jarup et al., 1998; Kamiyama et al., 1995; Kazantzis, 1978; Liu et al., 1998a Liu et al., , 1998b Liu et al., , 2000 Min et al., 1986 Min et al., , 1996 Nordberg and Nordberg, 2000; Nordberg et al., 1985; Oteiza et al., 1999; Sarkar et al., 1998; Zalups and Ahmad, 2003; Zalups et al., 1992) .
Experimental evidence indicates that Cd 2+ may interact with membrane transporters involved in the uptake of nutritive metals, such as Ca 2+ , Fe, and Zn, as a means to gain entry into target cells of organs affected adversely by this metal. This uptake has been proposed recently to occur through a mechanism of ionic mimicry (Zalups and Ahmad, 2003) , whereby Cd 2+ mimics the divalent cationic species one or more of these nutritive metals at the binding site of one or more carrier proteins and/or channels that transport these metals.
There is also experimental evidence supporting the hypothesis that Cd 2+ can form linear II coordinate covalent complexes with certain sulfhydryl-containing biomolecules, such as GSH, Cys, or Hcy in certain compartments of the body (Rabenstein, 1989; Rabenstein et al., 1983) . Much like mercuric conjugates of these molecules, the Cd-containing complexes may serve or behave as molecular mimics of endogenous amino acids, oligopeptides, organic anions, or organic cations at the site of membrane transporters of these substrates.
Receptor-mediated endocytosis of a Cd 2+ -protein complex, such as CdMT or Cd-albumin, also appears to be an important mechanism by which Cd 2+ is taken up by some epithelial cells. All of these potential mechanisms of uptake will be discussed in relation to individual organs in the following sections.
Mimicry and the hepatic transport of Cd
2+
Following oral exposure, Cd 2+ is absorbed by the intestines and subsequently delivered to the liver by portal blood. In the liver, Cd 2+ is taken up avidly from sinusoidal blood by hepatocytes. Cd 2+ is also taken up preferentially by the liver following parenteral exposure (ATSDR, 2003b; Liu et al., 2001; Zalups, 2000b) . For example, as much as 60% of a nontoxic dose of Cd 2+ (5 Amol/kg) has been shown to accumulate in the liver of rats within 1 h after intravenous administration (Zalups, 2000b) . It has also been shown in rats injected intravenously with a low dose CdCl 2 , G-S-Cd-S-G, or Cys-S-Cd-S-Cys, that less than 1% of the dose of Cd 2+ remained in the blood after 1 h. This indicates that Cd 2+ is extracted from the blood very rapidly by the liver and other organs and tissues (Zalups, 2000b) . Of the Cd 2+ remaining in the blood, approximately 50% is distributed among the cellular components of blood, with the majority being present in erythrocytes. It has been suggested that the absorption of Cd 2+ by erythrocytes may be mediated by an anion exchanger (Dawson and Ballatori, 1995) .
Although the mechanisms by which Cd 2+ is taken up across the sinusoidal membrane of hepatocytes remain unclear, several hypotheses to explain this transport have been proposed. One possibility is that Cd 2+ may mimic other elements or metals at the site of membrane transporters or channels (via some form of ligand exchange reaction) in the sinusoidal membrane of hepatocytes. It is also thought that Cd 2+ may bind to proteins that are taken up into hepatocytes via receptor-mediated endocytosis.
One membrane transporter that is likely involved in the sinusoidal uptake of the cationic form of Cd 2+ is DMT1. This transporter has been cloned and it has been characterized as a proton-coupled Fe transporter (Gruenheid et al., 1995; Gunshin et al., 1997) . In hepatocytes, DMT1 is localized in the sinusoidal membrane (Trinder et al., 2000) . Although DMT1 has not been implicated in the uptake of Cd 2+ in hepatocytes, it has been shown to participate in Cd 2+ transport in enterocytes (Elisma and Jumarie, 2001; Park et al., 2002; Tallkvist et al., 2001 ) and distal tubular cells (Olivi et al., 2001; Friedman and Gesek, 1994 Shaikh, 1991, 1992) (Souza et al., 1997) . Receptor-mediated and fluid-phase endocytosis account for a large amount of membrane turnover and fluid absorption in hepatocytes (Oka et al., 1989) . The endocytosis of transferrin and ferritin is one of the bestcharacterized forms of receptor-mediated endocytosis in hepatocytes and represents a major pathway in the hepatic uptake of Fe (Mack et al., 1983; Morgan and Baker, 1986; Osterloh and Aisen, 1989) . It has been shown that Cd 2+ may substitute for Fe 2+ at the site of DMT1, thus one would not be surprised to find that this substitution may also occur at the site of one or more Fe-binding proteins, such as ferritin. Indeed, ferritin has been shown to bind Cd 2+ (Huebers et al., 1987; Price and Joshi, 1983) . Therefore, it has been hypothesized that Cd-ferritin complexes may be endocytosed by hepatocytes in a means similar to that characterized for Fe-ferritin (Zalups and Ahmad, 2003) . It is also important to note that albumin, which is the most abundant plasma protein, is a potential carrier of Cd 2+ in blood, and thus endocytosis of Cd-albumin complexes may serve as a route for the hepatic entry of Cd 2+ . Furthermore, the intracellular metal binding protein, MT, binds Cd 2+ readily (Cherian and Goyer, 1978; Kägi and Vallee, 1960; Scheuhammer and Cherian, 1986) and CdMT complexes may be, under certain circumstances, transported into cells via receptor-mediated endocytosis.
It is important to note that within hepatocytes, a significant amount of Cd 2+ is bound to MT. When hepatocellular necrosis and/or apoptosis is/are induced, it has been hypothesized that complexes of CdMT are released into systemic circulation (Dudley et al., 1985) . Some of this Cd 2+ is delivered to the kidneys, where it is filtered by the glomeruli and is then reabsorbed by the epithelial cells of the proximal tubule (Dudley et al., 1985; Foulkes, 1978; Webb, 1986) . Importantly, CdMT has been implicated as the primary form of Cd 2+ that induces renal tubular injury and death (Cherian and Nordberg, 1983; Cherian et al., 1976; Dorian et al., 1992; Diezi, 1987, 1989; Murakami et al., 1983; Nordberg et al., 1975; Zalups et al., 1992) . Cd 2+ may also be transported out of hepatocytes back into the sinusoidal blood. Several transport proteins that may be involved in this transport include the organic anion transporting polypeptides, OATP1, OATP2, and OATP4 (Cattori et al., 2001; Jacquemin et al., 1994; Kullak-Ublick et al., 1994) , the organic cation transporter, OCT1 (Grundemann et al., 1994) , the metal transport protein, MTP1 (Abboud and Haile, 2000) and amino acid or peptide transporters that are localized in the sinusoidal plasma membrane. Although these carriers have not been implicated in the transport of metals out of hepatocytes, most of them are multi-specific transporters and may be able to carry metal ions or conjugated forms of metals.
Various lines of evidence indicate that a fraction of the Cd 2+ that enters into hepatocytes is secreted into the bile, and is subsequently delivered to the duodenum for excretion in the feces (Cherian and Vostal, 1977; Leslie et al., 2001 ). Evidence from thin-layer chromatography of bile from CdCl 2 -treated animals indicates that Cd 2+ is transported from the hepatocyte into bile as a GSH S-conjugate (presumably as G-S-Cd-S-G) by a carrier-mediated process (Cherian and Vostal, 1977) . Though a specific carrier has not been identified for this transport, MRP2 is a possible candidate. This transporter is localized in the canalicular membrane and has been shown to mediate the transport of GSH, GSSG, and GSH S-conjugates out of hepatocytes (Heijn et al., 1997; Keppler et al., 1998; Leier et al., 1996 Leier et al., , 2001 . The structural similarities between G-S-Cd-S-G and GSSG provide a strong rationale for the hypothesis G-S-Cd-S-G may act as a mimic of GSSG at the site of this transporter.
Molecular mimicry and the renal transport of Cd
2+
The kidney is one of the primary organs affected adversely in humans following chronic oral or inhalation exposure to Cd 2+ (ATSDR, 2003b; Friberg, 1950) . The deleterious effects of Cd 2+ on the kidneys was realized when factory workers producing nickel-cadmium batteries were exposed to cadmium oxide dust and cadmium fumes. The renal function of these workers was altered significantly, resulting in proteinuria and a lowered rate of glomerular filtration (Friberg, 1950) .
Mechanisms of proximal tubular uptake of Cd
2+
The majority of Cd 2+ found in the kidney is localized in the epithelial cells lining the proximal tubule (Felley-Bosco and Diezi, 1989) . Indeed, studies in isolated perfused proximal tubules from the rabbit (Robinson et al., 1993) and cultured proximal tubular cells (Endo, 2002; Endo et al., 1998a Endo et al., , 1998b Endo et al., , 1998c Endo et al., , 1998d Endo et al., , 1999 exposed to CdCl 2 provided direct evidence that Cd 2+ is taken up in a cationic form by proximal tubular epithelial cells. As these experiments utilized CdCl 2 , the data obtained may not represent accurately physiological processes that occur in vivo. Owing to the high affinity that Cd 2+ has for thiol-containing biomolecules, such as GSH and Cys, likely species of Cd 2+ that are presented to the luminal membrane of proximal tubular cells are Cd complexes of these molecules, for example, G-S-Cd-S-G or Cys-S-Cd-S-Cys. In addition, since g-glutamyltransferase and cysteinylglycinase are present in abundance in the luminal plasma membrane of proximal tubular cells, it is likely that G-S-Cd-S-G is not taken up as an intact complex. As Cys-S-Cd-S-Cys is the primary product formed by the actions of these enzymes on G-S-Cd-S-G, it is more likely that this Cys-complex is a transportable form of Cd 2+ at the luminal plasma membrane of proximal tubular epithelial cells. Indeed, in vivo microperfusion of renal proximal tubules in the rat has demonstrated that co-perfusion of Cys and Cd 2+ increased the tubular absorption of Cd 2+ by 82% (Felley-Bosco and Diezi, 1987) . Additional in vivo studies in rats have also shown that when CdCl 2 is administered subcutaneously with excess Cys, greater levels of Cd accumulate in the epithelial cells lining the proximal tubule (Murakami and Webb, 1981; Murakami et al., 1987) . Studies in rats show that when GSH or Cys are simultaneously injected (intravenously) with Cd 2+ , the renal uptake of Cd 2+ increases significantly (Zalups, 2000b) . These studies also demonstrated that there is at least one luminal and one basolateral mechanism involved in the renal uptake of Cd 2+ (Zalups, 2000b) . Unfortunately, no studies to date have identified a specific luminal mechanism for the uptake of a Cd 2+ -Cys conjugate by proximal tubular or, for that matter, any other epithelial cells. As discussed previously, Cys-S-Hg-S-Cys is a structural mimic of cystine, and is transported across the luminal plasma membrane of proximal tubular epithelial cells by the cystine transporter, system b 0,+ . Given that Cd 2+ forms complexes with Cys, which are structurally similar to Cys-S-Hg-S-Cys, we can hypothesize Cys-S-Cd-S-Cys may be taken up by the same or one or more similar mechanism(s) that mediate(s) the uptake of Cys-S-Hg-S-Cys.
It is also possible that Cd 2+ is taken up from the proximal tubular lumen through a mechanism involving ionic mimicry following ligand exchange. There is unpublished support for this coming from our laboratory and from studies in which Cd 2+ has been shown to dissociate from MT under certain conditions (Scheuhammer and Cherian, 1986) . The process of ligand exchange would permit Cd 2+ to exchange from a protein or non-protein thiol to the binding site of a cation transporter, such as DMT1.
With respect to DMT1, there is some controversy regarding its localization in proximal tubular epithelial cells (Canonne-Hergaux and Gros, 2002; Ferguson et al., 2001 ). In one study by Ferguson et al. (2001) , immunolocalization of DMT1 with a polyclonal antibody revealed that DMT1 was present in the cytoplasm of rat proximal tubular cells and did not localize in the brush border membrane. In contrast, Canonne-Hergaux and Gros (2002), also using a polyclonal antibody, showed that DMT1 was localized in the apical membrane of mouse proximal tubular cells. If DMT1 is indeed present in the luminal membrane of proximal tubular cells, it may play a role in the transport of Cd 2+ into these cells. It is important to note that the observed discrepancies in the localization of DMT1 may be due to differences between the species used for these experiments and/or variations in the experimental protocols.
In addition to other mechanisms, Cd 2+ may gain entry into proximal tubular cells through Ca 2+ channels, yet there is no definitive evidence supporting this theory. However, Cd 2+ has been shown to utilize Ca 2+ channels in isolated cells from other organs, including liver and intestine Shaikh, 1991, 1992; Friedman and Gesek, 1994; Hinkle et al., 1987; Souza et al., 1997) . Given these findings, it is reasonable to hypothesize that Cd 2+ also utilizes Ca 2+ channels for its transport along the nephron. Endocytosis has also been postulated as an important mechanism for the transport of Cd 2+ into proximal tubular cells (Erfurt et al., 2003; Murakami et al., 1983; Zalups and Ahmad, 2003 ). It appears that CdMT is released from necrotic/apoptotic hepatocytes into hepatic circulation following chronic exposure to Cd 2+ (Dudley et al., 1985) . CdMT is small enough to be filtered freely at the glomerulus and then be taken up by the epithelial cells of the proximal tubule via an endocytotic mechanism (Dudley et al., 1985; Foulkes, 1978; Webb, 1986) . Indeed, the cells of the proximal convoluted tubule are the primary sites affected adversely by CdMT (Cherian and Nordberg, 1983; Dorian et al., 1992; Diezi, 1987, 1989; Murakami et al., 1983; Nordberg et al., 1975; Zalups et al., 1992) .
The basolateral entry of Cd 2+ into the proximal tubule has important implications in Cd 2+ nephrotoxicology. It is thought that the Cd 2+ present in the blood may be transported across the basolateral membrane of the proximal tubular epithelial cells as a conjugate of Cys or other nonprotein thiols. However, no specific mechanisms for this uptake have yet been identified. One potential candidate for this transport is OAT1. It has been shown to mediate the inward transport of Hg 2+ in the form of Cys-S-Hg-S-Cys, Hcy-S-Hg-S-Hcy, and NAC-S-Hg-S-NAC across the basolateral membrane of proximal tubular cells through a mechanism of molecular mimicry (Aslamkhan et al., 2003; . It is believed that at least some of the Cd 2+ in blood, especially after acute exposures, is in the form of G-S-Cd-S-G, Cys-SCd-S-Cys, and/or NAC-S-Cd-S-NAC. As these Cd 2+ conjugates are similar structurally to those of Hg 2+ , we can hypothesize that OAT1 not only acts as a basolateral point of entry for conjugates of Hg 2+ , but may also mediate the uptake of similar conjugates of Cd 2+ .
Mimicry and transport of Cd 2+ in the distal nephron
There is substantial evidence indicating that Cd 2+ may be taken up by distal segments of the nephron (Dorian et al., 1992; Felley-Bosco and Diezi, 1987; Ferguson et al., 2001; Friedman and Gesek, 1994; Olivi et al., 2001 ). It has been hypothesized that some of the Cd 2+ delivered to the luminal compartment of the distal nephron and collecting duct is taken up in an absorptive manner by DMT1, likely through some form of ligand exchange reaction. This hypothesis is supported in part by immunolocalization experiments demonstrating that DMT1 is present in the luminal plasma membrane of the epithelial cells lining the ascending thick limb of the loop of Henle, the distal convoluted tubule and the principal cells of the cortical collecting duct (Ferguson et al., 2001) . Additional support for this hypothesis comes in part from experiments demonstrating that Cd 2+ is a potent inhibitor of Fe 2+ uptake in cells derived from the distal nephron (Friedman and Gesek, 1994; Olivi et al., 2001 ). In one particular study, Friedman and Gesek (1994) (Friedman and Gesek, 1994) . Exposure of these cells to parathyroid hormone, which promotes Ca 2+ absorption in the distal nephron (Borke et al., 1990; Friedman, 1988) , markedly increased the cellular uptake of Cd 2+ . Furthermore, the observed Cd 2+ uptake was inhibited by the Ca 2+ channel antagonist, nifedipine, and was enhanced by the Ca 2+ channel agonist BAY K 8644 (Friedman and Gesek, 1994) . These data suggest that Cd 2+ may enter distal tubular epithelial cells via mechanisms of ionic mimicry whereby Cd 2+ mimics Ca 2+ at the site of Ca 2+ channels.
Mimicry and intestinal transport of Cd
2+
The duodenum and the proximal jejunum are responsible for the majority of the absorption of ingested Cd 2+ (Andersen et al., 1994) . Interestingly, the duodenum is also a major site of Fe 2+ absorption (Bothwell et al., 1979; Umbreit, 2000, 2002; Crichton, 1991) . These facts, as well as the similarity in ionic radius between Cd 2+ (0.95 2) and Fe 2+ (0.55 2), suggest that these two cations may utilize some of the same transport mechanisms. Indeed, in vivo experiments in rats indicate that Cd 2+ interferes with the intestinal absorption of Fe 2+ , suggesting that these two metal ions may utilize the same transport pathways (Bunn and Matrone, 1966; Hamilton and Valberg, 1974; Hill et al., 1963; Leon and Johnson, 1985; Schafer and Forth, 1984) . DMT1 is a likely candidate for this transport.
DMT1 is localized in the luminal plasma membrane of enterocytes and it appears to play a major role in the intestinal absorption of Fe 2+ (Canonne-Hergaux et al., 1999; Griffiths et al., 2000; Gunshin et al., 1997; Tandy et al., 2000; Trinder et al., 2000) . Moreover, it has been hypothesized that DMT1 may participate in the uptake of Cd 2+ (Elisma and Jumarie, 2001; Park et al., 2002; Zalups and Ahmad, 2003) . As with Hg 2+ , Cd 2+ is not normally found as an unbound cation anywhere in the body. In the lumen of the intestines, Cd 2+ is usually bound to nucleophilic binding sites on amino acids and protein-ligands. Thus, given that DMT1 has been characterized as a cation transporter (Gunshin et al., 1997) , it may seem unlikely that this carrier can utilize Cd 2+ as a substrate when it is conjugated to an amino acid, oligopeptide, or protein. Yet, it is important to realize that Cd 2+ can dissociate from its bound ligands under certain conditions (Scheuhammer and Cherian, 1986) . Considering this, we can hypothesize that when Cd 2+ is presented to a stronger nucleophilic ligand, it is released from the carrier ligand to bind to DMT1 or other transporters at the plasma membrane of the enterocyte, which allows it to be transported across the luminal plasma membrane as a cationic species. Indeed, numerous studies have provided evidence for the transport of Cd 2+ , by DMT1, as a cationic species (Elisma and Jumarie, 2001; Leazer et al., 2002; Lecoeur et al., 2002; Okubo et al., 2003; Park et al., 2002; Picard et al., 2000; Tallkvist et al., 2001) . Findings from Xenopus laevis oocytes have provided some of the most direct evidence for the transport of Cd 2+ by DMT1 (Gunshin et al., 1997; Okubo et al., 2003) . In oocytes microinjected with mRNA encoding DMT1, and then analyzed using two-microelectrode voltage-clamp techniques, the presence of Cd 2+ in the extracellular medium was shown to invoke a large inward current, indicating that Cd 2+ is a substrate of DMT1 (Gunshin et al., 1997) . Additionally, findings of Okubo et al. (2003) indicate that when oocytes are microinjected with mRNA encoding DMT1, and then subsequently exposed to CdCl 2 , the rates of inward Cd 2+ flux are much greater than those in control oocytes. Furthermore, this transport appears to be saturable, with a Michaelis-Menten constant (K m ) of approximately 1.0 AM (Okubo et al., 2003) .
Other investigators have also studied the expression of DMT1 at a molecular level in relation to the uptake of Cd 2+ (Park et al., 2002; Tallkvist et al., 2001) . Tallkvist et al. (2001) carried out experiments in an immortalized line of colonic (Caco-2) cells in which the expression of the gene for DMT1 was reduced following exposure to Fe 2+ . Interestingly, the uptake of Cd 2+ was also reduced in these cells. The decrease in the uptake Cd 2+ correlates well with the reduction in DMT1 gene expression, suggesting that the uptake of Cd 2+ is linked to the expression of DMT1. These data were confirmed recently by in vivo studies in rats (Park et al., 2002) . Rats were fed a diet either deficient in Fe or supplemented with Fe for 4 weeks, following which animals were given an oral dose of CdCl 2 . The mRNA levels of DMT1 in the small intestine of the animals fed the Fedeficient diet were 15-fold greater than those in animals fed the supplemented diet. In addition, the content of Cd 2+ in the small intestines of animals with depleted Fe stores was significantly greater than that in rats fed a supplemented diet. The Cd 2+ content in the duodenum was approximately 10-fold greater than that in other organs tested. These data provide strong evidence supporting the hypothesis that DMT1 mediates the intestinal uptake of Cd 2+ . Additional studies in Caco-2 cells corroborated the aforementioned findings (Bannon et al., 2003) . Stable transfection of Caco-2 cells with an antisense construct of DMT1 successfully bknocked downQ the activity of DMT1 in these cells. The uptake of Fe 2+ , Pb 2+ , and Cd 2+ was decreased in these cells, indicating that DMT1 plays a mechanistic role in the uptake of these metals by enterocytes. Collectively, these molecular studies make an important contribution to understanding the intestinal disposition and transport of Fe 2+ and Cd 2+ . It is clear that dietary Fe status has a significant effect on the expression of DMT1 (Anderson et al., 2002; Martini et al., 2002; Rolfs et al., 2002; Wareing et al., 2003; Zoller et al., 2001 Zoller et al., , 2002 and the uptake of Cd 2+ in the intestine (Berglund et al., 1994; Choudhury et al., 2001; Flanagan et al., 1978; Fox et al., 1980; Groten et al., 1992) . This is particularly evident in pregnant rats (Leazer et al., 2002) . The requirement for Fe increases during pregnancy (Svanberg, 1975) , and thus the expression of DMT1 is elevated to compensate for the increased need for Fe. An elevation of DMT1 expression has also been observed in anemic (Choudhury et al., 2001) women. During pregnancy and other conditions where Fe stores are lowered, DMT1 expression increases through an Fe-response element. This in turn, appears to promote the enteric absorption of ingested Cd 2+ . Another potential mechanism involved in the uptake of Cd 2+ in enterocytes is a Zn transporter. Data from apical membrane vesicles from the small intestine of the pig indicate that the cationic form of Zn (Zn 2+ ) and Cd 2+ share a binding site on a transporter that does not take up Ca 2+ (Tacnet et al., 1990 (Tacnet et al., , 1991 . It has also been shown that Zn 2+ and Cd 2+ compete for a transporter that is independent of DMT1 (Elisma and Jumarie, 2001) . It has been hypothesized that Cd 2+ mimics Zn 2+ and is transported into enterocytes via a Zn 2+ transporter, such as the human, zinc-regulated zinc transporter 1 (hZTL1). This transporter, which is present in the luminal plasma membrane of enterocytes, is responsible for the inward transport of Zn 2+ in these cells (Cragg et al., 2001) . Given this, it is possible that Cd 2+ can mimic Zn 2+ at the site of hZTL1 to gain access to the intracellular compartment of enterocytes. Cd 2+ may also gain access to the cytosolic compartment of enterocytes via Ca 2+ channels present on the luminal plasma membrane of these cells. However, there is little data from studies in the intestine that support this hypothesis. On the other hand, the ability of Cd 2+ to compete with Ca 2+ at the site of membrane Ca 2+ channels has been well established in numerous in vitro models Shaikh, 1991, 1992; Friedman and Gesek, 1994; Hinkle et al., 1987; Souza et al., 1997) . Data directly supporting this phenomenon in animal models are lacking. In vivo studies in rats have demonstrated that in conditions where dietary Ca 2+ is restricted chronically, the intestinal uptake of orally administered Cd 2+ was increased greatly (Felley-Bosco and Diezi, 1992) . From these studies, we can postulate that Cd 2+ may serve or behave as a mimic of Ca 2+ at the sites of one or more Ca 2+ transporters to gain entry into enterocytes. Foulkes (1985 Foulkes ( , 1988 Foulkes ( , 2000 and Foulkes and McMullen (1987) have proposed a two-step mechanism of Cd 2+ transport across the luminal plasma membrane of enterocytes. The first step was postulated to involve binding of Cd 2+ to the plasma membrane. This binding was susceptible to chelators, such as EDTA, but was insensitive to changes in temperature. The second step was shown to be temperature-sensitive and chelator-insensitive and likely represented the actual flux of Cd 2+ across the luminal plasma membrane into the intracellular compartment of the enterocytes. This second step likely involves one or more of the transport mechanisms alluded to above.
Uptake of Cd 2+ across the plasma membrane of enterocytes may also occur in a manner where Cd 2+ is bonded to amino acids or peptides. It has been established that Cd 2+ forms linear II coordinate covalent complexes with thiolcontaining biomolecules such as Cys (Cys-S-Cd-S-Cys) or GSH (G-S-Cd-S-G) (Rabenstein, 1989) . As mentioned above, inasmuch as ingested food contains an abundance of such molecules, it is likely that Cd 2+ is presented to the plasma membrane of enterocytes as a complex of one or more of these molecules. Although a certain amount of ligand exchange occurs with Cd 2+ ions (allowing the transport of the cationic species of Cd 2+ ), it is highly probable that a substantial fraction of the Cd 2+ taken up at the luminal plasma membrane of enterocytes is, at least initially, bound to an amino acid or peptide ligand. Though the transport of S-conjugates of Cd 2+ has not been studied directly in the intestine, we can form an hypothesis regarding this transport based on the information available for the transport of S-conjugates of Hg 2+ . Like Cys-S-Hg-SCys and G-S-Hg-S-G, the molecules Cys-S-Cd-S-Cys and G-S-Cd-S-G are similar structurally to cystine and GSSG. These similarities in molecular structure lead us to hypothesize that such complexes may serve as mimics of endogenous molecules at the site of membrane transporters of these mimicked molecules. It should be noted that numerous studies have shown that G-S-Hg-S-G is transported out of the liver into the biliary tree, where it is broken down to form Cys-S-Hg-S-Cys before entering the duodenum (Ballatori et al., 1998; Dutczak and Ballatori, 1992; Norseth and Clarkson, 1971; Wang et al., 2000) . Experimental evidence suggests that Cd conjugates of GSH are likely handled in the same manner. Indeed, the findings of Cherian and Vostal (1977) indicate that Cd 2+ is transported out of bile as a conjugate of GSH. Based on these findings and the fact that the duodenal contents are rich in amino acid and peptides, it is reasonable to suggest that a significant fraction of absorbed Cd 2+ is taken up as a conjugate of these ligands by one or more amino acid and/or peptide transporters. To our knowledge, the involvement of these amino acid carriers in the transport of Cd 2+ -thiol complexes has not been investigated.
The possibility of endocytosis of Cd-peptide complexes in the intestine cannot be ruled out. As endocytosis of CdMT has been implicated as a means of Cd 2+ uptake in other organs, it is possible that Cd 2+ is absorbed via endocytosis along with various polypeptides.
The similarities between the uptake of Fe 2+ and Cd 2+ at the luminal plasma membrane of enterocytes leads us to postulate that these two metals may utilize a common mechanism for efflux at the basolateral membrane of enterocytes. The basolateral metal protein transporter 1, (MTP1/Ferroportin 1/Ireg1), has been identified in enterocytes, and is thought to participate in the absorption of dietary Fe by mediating the export of this metal across the basolateral plasma membrane into portal circulation (Abboud and Haile, 2000; Donovan et al., 2000; McKie et al., 2002) . Although there is no evidence to support a role for MTP1 in the intracellular to extracellular transport of Cd 2+ , this transporter may be nonetheless involved. A second carrier protein thought to be involved in the export of Fe into the circulation is hephaestin (Vulpe et al., 1999) . Immunolocalization experiments in IEC-6 cells isolated from the small intestine have identified hephaestin in the perinuclear region of the cells. Although this protein has also been detected on the plasma membrane, the labeling was weak and the exact region of membrane to which it is localized was not determined (Frazer et al., 2001; Simovich et al., 2002) . It has been suggested that this protein may mediate the intracellular transport of Fe, and possibly Cd 2+ , to MTP1. Moreover, if hephaestin is present on the basolateral plasma membrane, it may function in conjunction with MTP1 to transport Fe 2+ , and maybe Cd 2+ , out of enterocytes (Chung and Wessling-Resnick, 2003) .
In addition, Cd 2+ may exit the basolateral membrane of the enterocyte via a Zn 2+ transporter. An interaction between Zn 2+ and Cd 2+ has been demonstrated indirectly in several in vivo and in vitro models (Cotzias et al., 1961 (Cotzias et al., , 1962 Elisma and Jumarie, 2001; Jacobs et al., 1983) . A potential candidate for this efflux is the Zn 2+ transporter ZnT-1 (McMahon and Cousins, 1998; Palmiter and Findley, 1995) . ZnT-1 was first identified in rat kidney, and it is thought to play an important role in the absorption of Zn 2+ (Palmiter and Findley, 1995) . Present in the basolateral membrane of rat enterocytes (McMahon and Cousins, 1998) , ZnT-1 likely mediates the inward to outward transport of Zn 2+ (Palmiter and Findley, 1995) . The basolateral localization of this transporter and its postulated role in the export of Zn 2+ supports the hypothesis that this carrier may also participate in the outward flux of Cd 2+ across the basolateral membrane of enterocytes.
There is evidence indicating that Cd 2+ may be a competitive inhibitor of Ca 2+ at the site of the intestinal Ca-ATPase present on the basolateral plasma membrane of enterocytes (Verbost et al., 1987; Schoenmakers et al., 1992) . It has been suggested that Cd 2+ utilizes this carrier for its transport out of the enterocyte into portal and systemic circulation. Inasmuch as Cd 2+ has been shown to act as an ionic mimic of Ca 2+ in other organs and cellular models Shaikh, 1991, 1992; Friedman and Gesek, 1994; Hinkle et al., 1987; Souza et al., 1997) , it is reasonable to postulate that it may also do so at the site of the intestinal Ca-ATPase.
Mimicry of Cd 2+ in testis
The testes are another target affected adversely by Cd 2+ (Gunn et al., 1963a (Gunn et al., , 1963b Kar and Das, 1960; Parizek, 1957; Parizek and Zahor, 1956 ). Acute testicular necrosis and the destruction of the seminiferous tubules have been shown to occur in rats and mice after a single injection of Cd 2+ . The mechanism by which Cd 2+ gains access to the intracellular compartments of the cells of the testes is unclear. However, several studies have shown that Cd 2+ may gain access to these cells by acting as a mimic of Zn 2+ at the site of Zn 2+ transporters (King et al., 1999; Waalkes and Perantoni, 1988; Waalkes and Poirier, 1985) . Experiments using interstitial cells isolated from the testes of rats demonstrated that the Cd 2+ uptake into these cells was inhibitable by Zn 2+ and N-ethylmaleimide, a sulfhydrylalkylating agent (Waalkes and Poirier, 1985) . These findings suggest that testicular uptake of Cd 2+ may be due to the activity of a Zn 2+ -transporter, as well as a transporter that carries thiol-conjugates of Cd 2+ (possibly as G-S-Cd-S-G or Cys-S-Cd-S-Cs). The latter may be an amino acid transporter, of which many have been identified in the testes (Wagner et al., 2001) . Subsequent studies of the interaction between Zn 2+ and Cd 2+ provided additional evidence for the participation of a Zn 2+ carrier protein in the transport of Cd 2+ (Waalkes and Perantoni, 1988) . By using isolated interstitial cells from rat testes, it was shown that there are passive and active mechanisms involved in the uptake of Cd 2+ . Although the passive uptake of Cd 2+ was not affected by Zn 2+ , the addition of Zn 2+ was able to inhibit significantly the active component of Cd 2+ uptake. In vivo experiments in mice demonstrated that the uptake of Cd 2+ in the testes was a saturable process that was competitively inhibited by Zn 2+ , but not by Ca 2+ (King et al., 1999) . The results of these experiments would suggest that a Zn 2+ transporter most likely mediates the testicular uptake of Cd 2+ . A possible candidate for this transport is hZTL1 or a similar Zn 2+ transporter (Cragg et al., 2001 ). The expression of this hZTL1 has not been characterized in testis. If present, it may be involved in the inward transport of Cd 2+ via a mechanism of ionic mimicry.
The Fe 2+ transporter DMT1 also represents a route of Cd 2+ entry in the testes. There are no data implicating DMT1 in the testicular transport of Cd 2+ , yet this transporter has been identified in the Sertoli cells of the testis. Thus, it may be responsible for the inward transport of Fe 2+ , and possibly Cd 2+ in these cells.
Mimicry and transport of Cd 2+ in breast
As discussed in the previous sections, ionic Cd 2+ or molecules containing Cd 2+ may act as ionic or molecular mimics, respectively, of endogenous cations or molecules. Additionally, Cd 2+ may serve as a functional mimic of certain endogenous molecules. In this instance, Cd 2+ would have the ability to elicit the normal physiological response induced by an endogenous molecule. Indeed, several studies have demonstrated that Cd 2+ may be a mimic of estrogen (estradiol) at the site of the estrogen receptor (Garcia-Morales et al., 1994; Martin et al., 2003; Stoica et al., 2000a) . Garcia-Morales et al. (1994) demonstrated in a breast-cancer cell line (MCF-7) that a 24-h exposure to CdCl 2 elicits the same physiological effect that is observed following treatment with estradiol, indicating that these two chemicals can independently activate the estrogen receptor. Furthermore, exposure of the cells to CdCl 2 increased the transcription of mRNA encoding the progesterone receptor and increased the rate of growth of the exposed cells. Additional studies from these investigators provided data regarding the mechanism by which Cd 2+ is able to activate the estrogen receptor Stoica et al., 2000a) . These data indicate that Cd 2+ , like estradiol, activates the estrogen receptor by binding to the hormone-binding domain. Through its interactions with specific amino acids, Cd 2+ changes the conformation of the receptor to that created by the binding of estradiol Stoica et al., 2000a) . It is important to note that Cd 2+ does not normally exist in an unbound state in physiological solutions (Zalups and Ahmad, 2003) , thus data obtained from studies in which cells were treated with CdCl 2 may not accurately represent the physiological events that occur in vivo. However, subsequent in vivo studies in rats provided substantive support for the previous in vitro studies by demonstrating that Cd 2+ behaves as a functional mimic of estrogen in the uterus and mammary gland (Johnson et al., 2003) . In rats injected intraperitoneally with CdCl 2 , a 1.9-fold increase in uterine weight and an increase in milk protein synthesis in the mammary gland were observed. The addition of antiestrogen blocked the effects of Cd 2+ on these tissues, suggesting that Cd 2+ and estradiol are utilizing the same pathway (Johnson et al., 2003) . Collectively, these data indicate that Cd 2+ may function as a functional mimic of estradiol at the site of the estrogen receptor. Furthermore, these data provide important information relevant to the development of hormonerelated diseases such as breast cancer.
Lead
Lead (Pb) is a bluish-gray metal that occurs naturally in the earth's crust. It can exist as a Pb salt or as metallic Pb. Humans continue to be exposed to Pb through many different means. During the years when leaded gasoline was the primary source of fuel for automobiles, large quantities of Pb were added to the environment, especially in proximity to the major highways and thoroughfares. Additionally, up until 1978, much of the paint used in homes contained as much as 40% Pb (ATSDR, 2003c) .
Children are particularly sensitive to the effects of the inorganic form of Pb (Pb 2+ ), and are still being exposed to this toxic metal by playing with and ingesting soil contaminated with Pb 2+ . Eating, inhaling, and coming in dermal contact with older paints containing Pb 2+ are also common routes of exposure. Occupational exposure to Pb 2+ can occur in work places utilizing welding and in the manufacture of Pb-containing batteries, lead smelting and refining, and the production of pottery. It is estimated that, between 0.5 and 1.5 million, workers are exposed to Pb 2+ each year in his/her workplaces (ATSDR, 2003c) . Pb 2+ has been shown to have serious effects in the nervous, circulatory, skeletal, renal, hematopoietic, and endocrine systems (ATSDR, 2003c; Goyer, 1993; National Research Council, 1993) . Pb 2+ poisoning is more common in children than adults and is characterized by neurological symptoms such as headache, convulsions, ataxia, learning disorders, and hyperactive behavior (Blackman, 1937; Goyer, 1993; Needleman et al., 1990) . The effects of Pb 2+ on the cardiovascular system are contradictory. While a number of clinical studies have suggested that there is a relationship between the exposure to Pb 2+ and elevated blood pressure, an equal number of studies have found no correlation between the two (ATSDR, 2003c; Goyer, 1993) . The Environmental Protection Agency (EPA), however, has identified elevated blood pressure as a symptom of Pb 2+ poisoning (EPA, 1989) . The skeletal system, specifically bone, is a major site for the accumulation of Pb 2+ . This accumulation has been shown to compromise some ability of bone cells to respond to hormones and also may result in alterations in the plasma levels of 1,25-dihydroxy-vitamin D 3 (Goyer, 1993; Pounds et al., 1991) . Long-term exposure to Pb 2+ may also result in a nephropathy or renal adenocarcinoma (Baker et al., 1980; Buchet et al., 1980; Cooper et al., 1985; Fowler, 1993; Lilis, 1981; Goyer, 1982 Goyer, , 1993 Selevan et al., 1985) .
Despite the severe clinical consequences of Pb 2+ exposure, the mechanisms by which Pb 2+ enters target cells are not well understood. To date, there are several putative mechanisms to explain the uptake of Pb 2+ in target cells, and some of these may involve ionic mimicry. Early studies of Pb 2+ transport in rats have shown a relationship between the toxicity of Pb 2+ and Fe deficiencies (Six and Goyer, 1972) . Specifically, the toxicological signs of Pb 2+ exposure, such as the urinary excretion of y-aminolevulinic acid, were greater in rats fed an Fe-deficient diet than in rats fed a normal diet (Six and Goyer, 1972) . Epidemiological studies of children have demonstrated a relationship between Fe status and blood levels of Pb 2+ (Brandman et al., 2001; Schell et al., 2003) . Children who were Fe-deficient and were living in environments containing high levels of Pb 2+ had higher blood Pb 2+ concentrations than children whose iron levels were normal (Brandman et al., 2001) . Furthermore, Schell et al. (2003) found that the blood levels of Pb 2+ in newborns were related inversely to the Fe status of the mothers. Owing to the observed interaction between Fe   2+ and Pb 2+ , it can be hypothesized that these two metals utilize one or more of the same transport mechanisms, perhaps the Fe 2+ transporter, DMT1. Data implicating DMT1 in the transport of Pb 2+ come in part from studies in which the overexpression of DMT1 in yeast and human fibroblasts was shown to increase the transport of Pb 2+ in these cells (Bannon et al., 2002) . This increased level of Pb 2+ transport was inhibited by Fe 2+ , which is a known substrate of DMT1 (Gruenheid et al., 1995; Gunshin et al., 1997) . Contrary to these findings are data from studies carried out in Caco-2 cells in which the expression of DMT1 had been bknocked downQ (Bannon et al., 2002) . These data suggest that when the expression of DMT1 has been reduced, the uptake of Fe 2+ decreases, but the uptake of Pb 2+ is unchanged. Since the uptake of Fe
2+
and Pb 2+ was similar in the wild-type Caco-2 cells, it was suggested that DMT1 mediates some of the uptake of Pb 2+ in these cells, but that this uptake likely does not represent the main mechanism involved in the uptake of Pb 2+ (Bannon et al., 2002) . Considering all of these findings, it does appear that Pb 2+ can be transported by DMT1, probably via a mechanism of molecular mimicry where Pb 2+ mimics Fe 2+ to gain access to the intracellular compartment of cells at the site of this transporter.
An interaction between Pb 2+ and Ca 2+ has been identified in numerous in vivo and in vitro models (Barton, 1984; Blake and Mann, 1983; Bogden et al., 1992; Goldstein, 1977; Goyer, 1995 Goyer, , 1997 Kapoor and van Rossum, 1984; Mahaffey et al., 1986; Simons, 1986a; Six and Goyer, 1970; Ziegler et al., 1978) . Studies in rats (Bogden et al., 1992; Six and Goyer, 1970) , humans (Ziegler et al., 1978) , ligated intestinal loops of the chicken (Mykkänen and Wasserman, 1981) , and perfused intestinal loops of the mouse (Flanagan et al., 1979) (Mahaffey et al., 1986 ). It appears that low dietary intake of Ca 2+ can lead to higher levels of Pb 2+ in blood. The reverse of this relationship was also shown (Barton, 1984; Blake and Mann, 1983; Bogden et al., 1992) . High doses of Ca 2+ were associated with lowered blood levels of Pb 2+ in rats (Barton, 1984; Bogden et al., 1992) and humans (Blake and Mann, 1983 Hinkle, 1997a, 1997b; Reuter, 1983; Simons, 1993; Simons and Pocock, 1987) . Simons and Pocock (1987) Hinkle (1997a, 1997b) Kerper and Hinkle, 1997a) and bovine brain capillary endothelial cells (Kerper and Hinkle, 1997b) (Pfleger and Wolf, 1975) . More recently, Simons (1986a) suggested that Pb 2+ replaces Ca 2+ at the site of an active transporter of Ca 2+ . Furthermore, studies in human red blood cell ghosts provided direct evidence indicating that Pb 2+ is actively transported by a Ca 2+ -ATPase (Simons, 1988) . The maximum velocity (V max ) for this transport was estimated to be 11 mmol Â cell À1 Â h À1 while the K m was calculated to be approximately 0.5 AM.
Anion exchangers have also been implicated in the transport of Pb 2+ into erythrocytes (Bannon et al., 2000; Simons, 1986b Simons, , 1993 . Using resealed erythrocyte ghosts, Simons (1986b) demonstrated that over 90% of the uptake of Pb 2+ could be attributed to transport via an anion exchanger. He showed that inhibitors of anion exchangers (DIDS, 4-acetamido-4V-isothiocyanostilbene-2,2V-disulphonic acid (SITS), phloretin, furosemide, and bumetanide) blocked nearly all of the Pb 2+ uptake in erythrocyte ghosts. (Simons, 1986b (Simons, , 1993 . Subsequent studies in human erythrocytes have provided further support for the findings of Simons (1986b Simons ( , 1993 , confirming that that the transport of Pb 2+ into erythrocytes is mediated by an anion exchanger (Bannon et al., 2000) . In addition, the uptake of Pb 2+ by immortalized renal distal tubular (MDCK) cells was found to be dependent on time of exposure and temperature. This transport, however, was not affected by DIDS, indicating that it is not mediated by an anion exchanger (Bannon et al., 2000) .
Interestingly, experiments in rats with cannulated bile ducts indicate that Pb 2+ can be transported as a GSH Sconjugate (Alexander et al., 1986) . After an injection of DEM, cyclohexene oxide, or methyl iodide, which reduced intracellular concentrations of GSH, the biliary secretion of Pb 2+ was reduced significantly. Though the transport of a GSH-Pb 2+ complex was not demonstrated directly, these data suggest that such a complex may be a transportable form of Pb 2+ , possibly at the site of a GSSG transporter. Endocytosis of Pb 2+ -protein complexes may also serve as a route for the entry of this metal into cells. Oskarsson et al. (1982) and DuVal and Fowler (1990) identified a 63,000-dalton protein in a cytosolic fraction of rat kidneys that binds Pb 2+ . This protein was later identified as alpha-2-microglobulin (Fowler and DuVal, 1991) . In contrast, Pb 2+ -binding proteins (PbBPs) in the human kidney have been identified as diazapine-binding inhibitor (DBI) and thymosin beta-4 (Smith et al., 1994 (Smith et al., , 1998 . Fowler and DuVal (1991) proposed that Pb 2+ , bound to PbBPs, enters cells, such as the proximal tubular epithelial cells, by some form of endocytosis. Once inside the cell, PbBPs containing Pb 2+ are directed to lysosomes, and subsequently to the nucleus. Whether or not mimicry is involved in the internalization of PbBPs is not clear. It would appear, however, that Pb 2+ bonds with alpha-2-microglobulin in order to gain access to the intracellular compartment of cells. Pb 2+ , like the cationic species of some of the other toxic metals, is also capable of acting as a functional mimic of endogenous ions at intracellular binding sites. It has been shown to be a functional substitute for Ca 2+ at the site of calmodulin (Goldstein and Ar, 1983; Habermann et al., 1983) , a protein that plays a role in the regulation of intracellular Ca 2+ (Stoclet et al., 1987) . In addition, the activity of protein kinase C may be affected by the binding of Pb 2+ . Normally, Ca 2+ is responsible for the activation of protein kinase C, which mediates cell division, cell-to-cell communication, and cytoskeletal organization. According to Goyer (1997) (Goldstein, 1984) , leading to edema, and possibly brain damage. Importantly, the endothelial cells in the brain accumulate Pb 2+ preferentially (Toews et al., 1978) , which can account, in part, for the severe neurological symptoms observed with Pb 2+ poisoning.
Selenium
Selenium (Se) is an essential element that is commonly found in rock formations and soil. It is rarely found in its elemental form in the environment, but is usually present as sodium selenite and sodium selenate. Se is essential for the proper function of intracellular antioxidant enzymes and has a recommended daily allowance of 55 Ag/day (ATSDR, 2003d) . This metal is not classified as a toxic metal, but rather, is considered to be essential for human health. Yet, it is unique in that it has been shown to act as a functional mimic of several endogenous molecules. For this reason, a discussion of Se is included in this review.
Se can be found in paint, certain types of glass, vitamin supplements, plastics, and fungicides (ATSDR, 2003d) . In addition, the ash released from the burning of coal is a major source of environmental contamination of Se. Inhalation or consumption of excess quantities of this metal may be harmful to humans (ATSDR, 2003d; Combs and Gray, 1998) . Indeed, inhalation of Se compounds, such as hydrogen selenide and selenium dioxide, results in serious injury to the respiratory tract (Dudley and Miller, 1941; Hall et al., 1951) , cardiovascular system (Wilson, 1962) , gastrointestinal tract (Holness et al., 1989; Glover, 1967; Wilson, 1962) , liver (Dudley and Miller, 1941; Hall et al., 1951) , and nervous system (Clinton, 1947; Glover, 1967) . Ingestion of excess Se has been shown to cause vision impairment, paralysis, and respiratory failure in livestock (ATSDR, 2003d) .
Little is known about the manner in which Se enters mammalian cells. Data from everted sacs of rat ileum indicate that the uptake of selenate across the luminal plasma membrane of enterocytes may be driven by a Na + gradient (Arduser et al., 1985) . Other experiments in isolated rat enterocytes showed that intracellular and extracellular GSH stimulates the uptake of Se (Anundi et al., 1984) . The addition of GSH to the extracellular solution of cultured enterocytes increased the cellular accumulation of Se. Interestingly, when the catabolism of intracellular GSH was inhibited, by inhibition of g-glutamyltransferase with serine-borate, the uptake of Se was reduced. These studies suggest that the transport of Se is dependent upon the products of GSH metabolism (Anundi et al., 1984) . In support of this theory, additional studies demonstrated that Cys, in addition to GSH, stimulates the uptake of Se in isolated perfused segments of distal jejunum (Senn et al., 1992) and ligated intestinal loops (Vendeland et al., 1992) . Interestingly, in the isolated segments of jejunum, GSH inhibited the uptake of Se while Cys stimulated its uptake. These data suggest that the transportable species of Se are not GSH S-conjugates, but are likely Cys S-conjugates of Se (Senn et al., 1992) . Indeed, subsequent studies in primary cultures of enterocytes isolated from sheep showed that SeCys complexes are transported readily across the luminal plasma membrane of these cells (Wurmli et al., 1989) . This transport was inhibited by the presence of various amino acids, indicating that, an amino acid transporter is involved in the uptake of this metal, perhaps by a mechanism involving molecular mimicry, similar to that utilized in the proximal tubular uptake of Cys-S-Hg-S-Cys.
Interestingly, Se (like Cd) appears to behave as a functional mimic of estrogen at the site of the estrogen receptor. Studies in MCF-7 cells have shown that Se, in the form of sodium selenite, binds to the hormone-binding domain of the estrogen receptor resulting in its subsequent activation (Stoica et al., 2000b) . Exposure to Se has also been shown to increase the transcription of the progesterone receptor. These findings have many important implications for the treatment and prevention of hormone-related diseases.
Another important function of Se is its role as an insulin mimic. According to Stapleton (2000) , an insulin mimic is any agent that can effectively elicit the effect of insulin on cells. The first apparent evidence of selenium's ability to mimic insulin comes from experiments in isolated rat hepatocytes (Ezaki, 1990) . The findings from these experiments demonstrate that selenate stimulates the transport of glucose in hepatocytes in a dose-dependent manner. This transport was associated with the insertion of the glucose transporters, GLUT-1 and GLUT-2, into the plasma membrane of the cells, a response similar to that induced by insulin.
The effect of selenate on the uptake of glucose was also studied in rat soleus muscle (Furnsinn et al., 1996) . Furnsinn et al. (1996) showed that selenate stimulated the uptake of glucose and increased the rate of aerobic and anaerobic glycolysis. Subsequent in vivo studies in streptozotocininduced diabetic rats (Berg et al., 1995; McNeill et al., 1991) and mice (Ghosh et al., 1994) indicate that treatment with selenate effectively lowers plasma levels of glucose. Insulin is involved in the regulation of cellular metabolic processes, such as carbohydrate and fatty acid metabolism (O'Brien and Granner, 1996) , glycogen synthesis (Shepherd et al., 1995) , glycolysis (Magnuson et al., 1989) , gluconeogenesis (O'Brien et al., 1990; Short et al., 1986) , fatty acid biosynthesis (Moustaid et al., 1994; Stapleton et al., 1990) , and the pentose phosphate pathway (Wagle et al., 1998) . Multiple studies have shown that selenate is able to mimic insulin in the above metabolic processes (Battell et al., 1998; Becker et al., 1996; Ghosh et al., 1994; Magnuson et al., 1989 ). An example of this effect was demonstrated in diabetic rats and mice exposed to selenate (Becker et al., 1996; Ghosh et al., 1994; Magnuson et al., 1989) . Oral administration of selenate to diabetic rats restored the expression of enzymes involved in glycogen synthesis and gluconeogenesis (Becker et al., 1996) to normal levels. Similarly, treatment of diabetic rats with selenate also restored the expression of enzymes involved in fatty acid biosynthesis and the pentose phosphate pathway (Ghosh et al., 1994; Magnuson et al., 1989) to normal levels. A characteristic effect of diabetes is a high plasma level of lipids. Interestingly, selenate reduced the plasma levels of lipids, triglycerides, cholesterol and free fatty acids in diabetic rats (Battell et al., 1998) . Collectively, the above data provide indirect evidence that selenate may act as a mimic of insulin in a variety of cellular processes. The clinical implications of these findings have yet to be determined.
Arsenic
Arsenic (As) is a highly toxic element found naturally in the earth's crust. When combined with anionic species of oxygen, chlorine, or sulfur, it is referred to as inorganic As (ATSDR, 2003e). Organic As is formed when As ions combine with carbon and hydrogen. Data from studies of animals have shown that organic forms of As are less toxic than the same dose of inorganic As (ATSDR, 2003e). Interestingly, high doses of organic As can produce the same toxicological effects as a lower dose of inorganic As (ATSDR, 2003e).
Inorganic As has long been recognized as a human poison and carcinogen (ATSDR, 2003e; EPA, 1999) . Numerous studies have shown that this metal has deleterious effects on the respiratory (Civantos et al., 1995; Dunlap, 1921; Lundgren, 1954; Morton and Caron, 1989; Pinto and McGill, 1953; Sandstrom et al., 1989) , neurological (Armstrong et al., 1984; Blom et al., 1985; Civantos et al., 1995; Feldman et al., 1979; Lagerkvist and Zetterlund, 1994) , and cardiovascular (Cullen et al., 1995; Jensen and Hansen, 1998; Lagerkvist et al., 1986 Lagerkvist et al., , 1988 systems. The most common and well-characterized sign of As poisoning is the development of skin lesions and warts (Bickley and Papa, 1989; Dunlap, 1921; Holmqvist, 1951; Lagerkvist et al., 1986; Mohamed, 1998; Perry et al., 1948; Pinto and McGill, 1953) .
Humans are exposed to As through environmental, dietary and occupational sources. Water contaminated with inorganic As is a major environmental issue, especially in areas having a rocky terrain. The importance of monitoring drinking water for As contamination was emphasized after millions of Bangladesh residents were poisoned by consumption of arsenic-containing well water . Soil contamination of inorganic As is also a concern in North America. Since children often play in (and may unintentionally eat) dirt, the ingestion of As-contaminated soil may be a primary source for childhood exposures. Humans may also be exposed to inorganic As upon ingestion of certain fish and various types of seafood, which can contain high levels of this metal. With regard to occupational sources of As in the United States, approximately 90% of all As used in industry is utilized in the bpressure-treatmentQ of wood. Workers involved in the treatment process or exposed to dust produced when the wood is cut are at higher risk for As poisoning. Inorganic As is also a component of pesticides used for treatment of cotton crops (ATSDR, 2003e).
The mechanisms of As uptake and elimination in target cells have been studied extensively, but unfortunately, are not completely understood. Like the transport of a number of other metals, the transport of As may be dependent on the co-transport of a GSH S-conjugate of As. In vivo studies in rats indicate that the biliary excretion of As is dependent upon the transport of GSH across the canalicular membrane of hepatocytes (Gyurasics et al., 1991) . Some studies have implicated the MRPs in the biliary export of As (Cole et al., 1994; Kala et al., 2000; Zaman et al., 1995) . Cole et al. (1994) transfected a line of cultured human hepatocytes (HeLa cells) with MRP1 and showed that this transfection confers a phenotype of As resistance upon these cells. Since the control cells remained susceptible to the effects of As, it can be postulated that MRP1 may be responsible for the transport of arsenic out of cells (Cole et al., 1994) . In support of this theory, studies in the soil nematode, Caenorhabditis elegans indicate that inactivation of the mrp1 gene increases the sensitivity of these organisms to As (Broeks et al., 1996) . Additional experiments in a line of lung cancer (SW-1573/S1) cells that had been transfected stably with MRP1 provided conclusive evidence that As and GSH are co-transported by this carrier (Zaman et al., 1995) . Subsequent experiments in rats with cannulated bile ducts demonstrated that MRP2 is involved in the transport of As-GSH complexes across the biliary canaliculus of hepatocytes (Kala et al., 2000) . Unfortunately, these experiments did not determine the actual structure of the As-GSH complex involved in this transport. It has been shown, however, that As and GSH form a complex consisting of three GSH molecules bonded to one As atom (As(GS) 3 ) (Scott et al., 1993; Delnomdedieu et al., 1994) . This complex is likely the species of As that is transported by MRP1 and MRP2.
Additional mechanisms involved in the uptake of As-GSH complexes were identified in a study utilizing microarray techniques (Liu et al., 2001) . The findings from this study indicate that rat hepatocytes cultured in As-containing media for 18 weeks had become tolerant to As and that this tolerance was due to an increased expression of glutathione S-transferase II, MRP1, MRP2, and P-glycoproteins. The authors of this study postulated that these mechanisms work in consort to reduce effectively the intracellular content of As in hepatocytes. A more short-term study was carried out in primary cultures of rat and human hepatocytes (Vernhet et al., 2001 ). Cells exposed to sodium arsenite and sodium arsenate for 8-48 h demonstrated a time-and dose-dependent increase in the expression of MRP2, providing additional evidence that this carrier may be involved in the transport of As. Additional studies in HeLa cells overexpressing MRP1 showed that As, as As(GS) 3 , is transported by this protein carrier. Furthermore, it was demonstrated that the formation of a tri-glutathione conjugate of As is required for its transport (Leslie et al., 2004) . These studies are supported by experiments in mice lacking g-glutamyltransferase, which identified As(GS) 3 and methyl arsenic di-glutathione (CH 3 As(GS) 2 ) in the urine of these mice (Kala et al., 2004) . MRP1 has been localized in the basolateral membrane of a line of cultured porcine renal proximal tubular epithelial (LLC-PK1) cells (Evers et al., 1996) , and thus may mediate the transport of As(GS) 3 and CH 3 As(GS) 2 from the blood into the intracellular compartment of these cells. Additional experiments using mice deficient in MRP1, MRP1a/1b, or MRP2 have demonstrated that administration of MK571, and inhibitor of MRPs, reduced the urinary excretion of As by 50% (Kala et al., 2004) . These experiments suggest that there is an additional transporter, other than MRP1, MRP1a/1b, or MRP2, which is involved in the transport of As complexes (Kala et al., 2004) .
MRP1 and MRP2 transport a growing number of substrates. Therefore, the role of molecular mimicry in the MRP-mediated transport of As is unclear. There are two possible explanations for the transport of As by the MRPs. Arsenic complexes may act as mimics of one or more substrate(s) that is/are normally transported by the MRPs. Alternatively, as As contamination in the environment has become more prevalent, MRPs have adapted to the changing needs of the cells in which they are localized, consequently broadening their substrate specificities.
Interestingly, As, in the form of arsenite has the apparent ability to act as a functional mimic of estrogen (estradiol) at the site of the estrogen receptor. Experiments in MCF-7 cells demonstrated that arsenite interacts with the hormonebinding domain of the estrogen receptor to activate this protein (Stoica et al., 2000c) . Similar to data for Cd 2+ and Se, arsenite was shown to increase the transcription of the progesterone receptor gene and increase the rate of cell growth. Furthermore, arsenite blocked the binding of estradiol to the estrogen receptor, suggesting that these two compounds utilize the same pathway. These data suggest that As may be a significant risk factor for the development of breast cancer and other hormone-related diseases.
Oxyanions of toxic metals
It has been noted that endogenous oxyanions, such as monovalent phosphate and sulfate, are similar structurally to oxyanions of several toxic metals (Clarkson, 1993; Wetter-hahn-Jennette, 1981) . The molecular structure of arsenate and vanadate are very similar to that of monovalent phosphate, while the molecules, chromate, molybdate and selenate are similar in shape and size to sulfate (Fig. 1) . Therefore, it is not surprising that the oxyanionic forms of toxic metals have been found to mimic monovalent phosphate or sulfate at the site of some membrane carrier proteins. For example, vanadate seems to interfere with the transport of monobasic phosphate at the sites of several different carriers. According to Clarkson (1993) , studies of vanadate in erythrocytes indicate that the inward flux is inhibitable by phosphate and by agents that inhibit the Cl À / HCO 3 À exchanger. More recent findings from studies of vanadate in HEK-293 cells demonstrated that vanadate can inhibit the uptake of phosphate at the site of the NaPi-3 cotransporter (Timmer and Gunn, 1998) . In addition, vanadate may act as a mimic of a phosphate molecule on the cytoplasmic side of the Na + -K + ATPase (Cantley et al., 1978a (Cantley et al., , 1978b Karlish et al., 1979) . The binding of a phosphate molecule, derived from ATP, is essential for the activity of this exchanger. Substitution of this phosphate with vanadate results in the inhibition of the Na + -K + ATPase (Cantley et al., 1978a; Karlish et al., 1979) .
Arsenate has also been shown to interact with monovalent phosphate at the sites of several different carriers. Experiments in osteosarcoma cells (ROS 17/2.8; Caverzasio et al., 1988) , bovine and rabbit renal brush border membrane vesicles (Schali et al., 1986; Vachon et al., 1991) , vesicles from the matrix of chicken cartilage (Montessuit et al., 1991) , and the luminal plasma membrane of rat intestine (Ishizawa et al., 1990) show that arsenate will compete with phosphate at the site of the sodium-dependent phosphate co-transporter. Additionally, arsenate has been shown to inhibit competitively phosphate transport at the site of an uncharacterized sodium-independent transporter (Azzarolo et al., 1991; Quamme et al., 1989) . Interestingly, arsenate does not inhibit the transport of phosphate across the sodium-dependent phosphate exchanger in human erythrocytes (Shoemaker et al., 1988) , indicating that there may be some specificity involved in the mimicry of phosphate by arsenate. Arsenate may act as a mimic of phosphate at intracellular sites as well. For example, a phosphate molecule is donated normally to 3-phosphoglyceradehyde to form 1,3-diphosphoglycerate, which in turn, donates a phosphate molecule to ADP to form ATP. Arsenate may substitute for the molecule of phosphate that is donated to 3-phosphoglyceraldehyde and results in the disruption of ATP synthesis (De Master and Mitchell, 1973) .
Sulfate has a tetrahedral structure similar to that of oxyanions of several metals, including selenate, molybdate, and chromate (Fig. 1B) . Early studies of sulfate transport in rat ileum indicate that molybdate competitively inhibits the uptake of sulfate, suggesting that these two compounds are substrates for the same transporter (Cardin and Mason, 1975; Mason and Cardin, 1977) . Subsequent studies in membrane vesicles from human placenta showed that molybdate and chromate are competitive inhibitors of sulfate (Shennan et al., 1988) . Furthermore, data from proximal tubular brush-border membrane vesicles from sheep demonstrate that sulfate and molybdate utilize the same transport system (Ryan et al., 1987) . Additional support for these findings come from in vivo studies in renal proximal tubules of rats showing that metals, such as selenate and molybdate, are transported by luminal and basolateral sulfate transporters (David and Ullrich, 1992) . Collectively, these findings indicate that metal compounds have the ability to act as functional mimics of the oxyanion sulfate at the sites of several different extracellular protein carriers.
Chromium has been shown to inhibit competitively the uptake of sulfate at the site of the anion exchanger in human erythrocytes (Ormos and Manyai, 1978) and placenta (Shennan, 1988) . Moreover, it has been shown that sulfate and chromate can inhibit the transport of molybdate into the enterocytes of the small intestine (Huisingh and Matrone, 1976) , while molybdate was able to inhibit the transport of sulfate (Shennan, 1988) . These data provide further evidence supporting the notion of molecular mimicry.
Summary
As humans are exposed to toxic metals in the workplace and environment, it is imperative that we understand how these metals affect essential cellular processes, and ultimately, human health. Molecules containing toxic metals have found ways to mimic endogenous molecules in order to gain access to target cells via essential transporters. Furthermore, some metals have been shown to mimic endogenous intracellular molecules, thereby interfering with essential cellular processes. Understanding how toxic metals interact with extracellular and intracellular proteins will prove to be important to the development of treatment regimes of diseases induced by exposure to these metals.
